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Abstract 
 
THE EXTERNAL GLOBUS PALLIDUS: BIDIRECTIONAL CONTROL OVER 
ANXIETY-RELATED BEHAVIOR MEDIATED BY CRFR1 
 
 
Albert Lee Joseph Hunt, Jr., B.S. 
 
 
Advisory Professor: Shane Cunha, Ph.D. 
 
 
Corticotropin-releasing factor receptor 1 (CRFR1), the principle receptor responsible 
for the anxiogenic activity of the stress peptide CRF, is abundantly expressed in the 
external globus pallidus (GPe) raising the question whether activity in the GPe is 
altered in response to stress. I show that CRFR1 expressing neurons are of the 
“prototypic” subtype of GPe neurons. I provide evidence of novel circuits from CRF 
neurons in stress-responsive nuclei, including the paraventricular nucleus of the 
hypothalamus (PVN) and the central nucleus of the amygdala (CeA), that provide 
excitatory input to the GPe. Additionally, I show that activation of CRFR1 neurons 
using Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) 
increases anxiety-related behavior and movement. I show that anxiety-related 
behavior and movement are decreased in response to activation of Npas1+ neurons, 
a class of neuron in the GPe that are primarily of the “arkypallidal” subtype. My 
evidence indicates that CRF neurons may project to the GPe to modulate anxiety-
related behavior and movement through differential synaptic input to distinct GPe 
neuronal subtypes. CRF to GPe circuits provide possible therapeutic avenues to treat 
anxiety disorders comorbid with basal ganglia neurodegenerative diseases that cause 
aberrant activity in the GPe such as Parkinson’s disease.    
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Introduction
	 2	
The Stress Response, HPA-axis, and Corticotropin-releasing factor  
 
Hans Selye is considered the father of stress research. After many years of 
experiments, he defined stress as the nonspecific response of the body to any 
demand for change or challenge to homeostasis. In 1936, Selye was the first to 
provide evidence of the physical effects of stress on the body. In what he termed “a 
typical syndrome,” he described three stages that occurred independent of what the 
“damaging agent” or stressor was. The first stage he termed the “Alarm Reaction.” 
Today, we would call this the activation of the HPA-axis which will be discussed in the 
following sections. The second stage, the “Stage of Resistance.” In this stage, the 
body attempts to counteract the changes that the stressful stimulus produced. Lastly, 
he termed the third stage, the “Stage of Exhaustion.” In this stage, the body has 
depleted all of its resources needed to repair itself back to a state of homeostasis. He 
believed that all three stages of this “syndrome” represented a collective effort of an 
organism to adapt to new conditions and coined this syndrome the “general adaptation 
syndrome.” Hans Selye’s paper “A syndrome produced by diverse nocuous agents” 
continues to serve as the foundation for future stress research (Selye 1936; Holsboer 
and Ising, 2010; Selye, 1950). 
Regulation of homeostasis in the presence of a stressor (lack of sleep, cell 
death, threat to life, working out; any threat to homeostasis) requires activation and 
initiation of multiple systems including the endocrine, nervous, and immune systems. 
The activation of these systems is known as the stress response (Carrasco and Van 
de Kar, 2003; Chrousos, 1992a). As a result of activation of the stress response, 
behavioral and physiological adaptations that increase an organism's chances for 
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survival when faced with a challenge to homeostasis are enacted through the 
sympathetic nervous system. Physiological changes initiated by the stress response 
include increased cardiovascular tone and respiratory rate. Also, the stress response 
suppresses activities in the body including inhibition of feeding, digestion, growth, and 
immune system functioning (Habib et al., 2001; Sapolsky, 2000). Some of the 
behavioral changes that occur when faced with a threat are increased arousal, 
improved cognition, and a reduction in the sensation of pain (Charmandari et al., 2005; 
Chrousos, 1992a). The main structures of the stress response are located in the 
paraventricular nucleus of the hypothalamus (PVN), the anterior lobe of the pituitary 
gland, and the adrenal gland. Collectively, these structures form the hypothalamic-
pituitary-adrenal (HPA)-axis. Additional neural structures involved in the stress 
response include the locus ceruleus (LC)-noradrenergic system, sympathetic 
adrenomedullary circuits, and parasympathetic systems (Chrousos, 1992b; Tsigos 
and Chrousos, 2002; Whitnall, 1993).  The HPA-axis, in combination with the efferent 
sympathetic/adrenomedullary system, represent the effector limbs by which the brain 
influences all body organs during exposure to a noxious stimuli (Gold et al., 1988). 
Corticotropin-releasing factor (CRF), also known as Corticotropin-releasing 
hormone (CRH), is a 41 amino acid peptide originally isolated from ovine hypothalamic 
extracts (Vale et al., 1981). Neurons located in the medial parvocellular subdivision of 
the PVN release CRF, the primary regulator of the HPA-axis, which travels through 
the hypophyseal portal to bind corticotrophs and stimulate the secretion of 
corticotropin, now known as adrenocorticotropic hormone (ACTH) from the anterior 
pituitary (Rivier and Vale, 1983; Vale et al., 1981). In fact, Selye predicted the 
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existence of an “X factor” that performed this function some 30 years before the 
discovery of CRF (Selye, 1950). Arginine-Vasopressin (AVP) released by AVP PVN 
neurons acts synergistically with CRF to amplify ACTH secretion, however AVP 
release does not result in ACTH secretion alone. Additionally, there is reciprocal 
positive interaction between CRF and AVP in the hypothalamus with each 
neuropeptide stimulating the secretion of the other (Smith and Vale, 2006; Tsigos and 
Chrousos, 2002). ACTH travels through the systemic circulation to the adrenal cortex 
and stimulates the synthesis and release of glucocorticoids, namely cortisol in humans 
or corticosterone (Cort) in mouse (Fig.1). Glucocorticoids act as the downstream 
regulators of the HPA-axis and act through two receptors; mineralocorticoid receptors 
(MRs) and glucocorticoid receptors (GRs). The main effects of the stress response 
are mediated through these intracellular receptors, which are expressed throughout 
the central nervous system (CNS) and the periphery and act as transcriptional 
regulators (Bamberger et al., 1996; Munck et al., 1984). Although the effects of 
glucocorticoids are generally beneficial, over activation of the HPA-axis may lead to 
negative symptoms associated with the stress response and eventually develop into 
pathologies. Examples of negative symptoms of HPA-axis overactivity are insulin 
resistance that leads to the promotion of visceral adiposity and hypertension, which 
can develop into diseases of adipose tissue metabolism (Fig.2) (Tsigos and Chrousos, 
2002). To prevent this over-activation, glucocorticoids are responsible for inhibiting 
further HPA-axis activation through GR mediated inhibition of PVN neurons that 
secrete CRF (McEwen, 1993; Munck et al., 1984). During the absence of a stressor 
both CRF and AVP are released in the portal system in a circadian rhythm resulting 
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in differing levels of basal Cort and ACTH at different times of day. CRF and AVP are 
released in greater amounts in the early morning (in human) stimulating the HPA-axis. 
The diurnal variations in Cort and ACTH are disrupted by activation of the stress 
response because the stress response alters their homeostatic balance (Chrousos 
and Gold, 1998; Horrocks et al., 1990).   
An interconnected network of brain nuclei that are simultaneously activated by 
stress and by CRF activity have been termed the central autonomic system (CAS) 
(Fig.3) (Saper, 2004). The primary brain structures within the CAS are the central 
nucleus of the amygdala, bed nucleus of stria terminalis (BST), PVN, the lateral 
parabrachial nuclei (PBI), locus ceruleus (LC), nucleus of the solitary tract (NTS), and 
the ventrolateral medulla (VLM). These CRF-rich nuclei are key to the processing of 
stress-relevant sensory information and generating an adaptive response to a stressor 
(Justice et al., 2008; Saper, 2004; Swanson et al., 2008).  
Catecholaminergic neurons located in the brainstem help to mediate HPA-axis 
functioning. The NTS conveys incoming sensory information from the cranial nerves 
to the PVN through long-range projections. Also, the NTS receives projections from 
key limbic regions that play a role in the behavioral responses to stress including the 
amygdala and prefrontal cortex (PFC) (Schwaber et al., 1982). Extensive innervation 
from catecholaminergic neuronal projections to the PVN from stress-responsive 
neurons in the A2/C2 region of the NTS stimulate the HPA-axis which induces CRF 
expression and release (Fig.3) (Cunningham et al., 1990; Cunningham and 
Sawchenko, 1988; Plotsky, 1987; Plotsky et al., 1989; Widmaier et al., 1988). 
Somatostatin, substance P, and enkephalin are expressed by some neurons located 
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in the NTS and play a role in the regulation of the HPA-axis as well (Saphier et al., 
1994; Sawchenko et al., 1990, 1988). Additionally, nonaminergic NTS neurons send 
projections to the PVN allowing them to participate in HPA-axis functioning. Also, 
neurons in the NTS that release glucagon-like peptide 1 are activated by physiological 
stressors ultimately leading to the release of ACTH via connections to the PVN (Kinzig 
et al., 2003). Undoubtedly, projections to the PVN from the NTS are critical for the 
proper functioning and activity of the HPA-axis. 
The PFC, hippocampus and amygdala play a major role in glucocorticoid 
release and behavioral responses to stress (Feldman et al., 1995; Forray and Gysling, 
2004; Jacobson and Sapolsky, 1991). These limbic regions do not project to the PVN. 
It is thought that these regions communicate with the PVN through intermediary 
neurons located in the BST and brainstem (Herman et al., 2005; Sawchenko et al., 
2007). The hippocampus has a role in the termination of the HPA-axis response to 
stress. Excitation of hippocampal neurons inhibits PVN neuronal activity and 
decreases glucocorticoid secretion (Rubin et al., 1966; Saphier and Feldman, 1987; 
Sapolsky et al., 1984). Lesion experiments provided evidence that similar to the 
hippocampus, the PFC has inhibitory tone on the HPA-axis (Diorio et al., 1993; 
Figueiredo et al., 2003).  However, unlike the hippocampus and prefrontal cortex, the 
amygdala activates the HPA-axis (Matheson et al., 1971; Van de Kar and Blair, 1999). 
Two CRF receptors exist, CRFR1 and CRFR2 (Fig.4) (Dautzenberg and 
Hauger, 2002). The primary receptor (based on binding affinity and CNS localization) 
for CRF, CRFR1, is responsible for the anxiogenic effect of CRF. CRFR1 knockout 
(KO) mice display remarkably reduced anxiety-related behavior and a blunted HPA-
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axis leading to the conclusion that CRFR1 is required for the anxiogenic effects of 
CRF, as well as activation of the HPA-axis (G. W. Smith et al., 1998). Consistent with 
the receptor’s involvement in anxiogenic behavior, CRF KO mice show impaired 
adrenal responses to various stressors. Additionally, the ACTH response to stress in 
CRF KO mice is diminished compared to wildtype (WT) mice (Kageyama et al., 2011). 
However, selective knockout of CRFR1 in various brain systems has led to contrasting 
effects on anxiety-related behavior. For example, deletion of CRFR1 broadly in 
excitatory neurons leads to decreased anxiety-related behavior, whereas selective 
deletion in dopaminergic neurons increases anxiety-related behavior (Refojo et al., 
2011).  
In contrast, CRFR2 KO mice do not have a clear phenotype compared to the 
anxiolytic effect of CRFR1 KO mice. CRFR2 deficient mice display normal basal levels 
of ACTH and Cort providing additional evidence that CRF/CRFR1 signaling is 
responsible for activation of the HPA-axis. However, CRFR2 KO mice have increased 
HPA-axis activity in response to a stressor suggesting that CRF/CRFR2 signaling 
serves to oppose CRFR1-mediated control of ACTH and Cort release (Deussing and 
Wurst, 2005; Kormos and Gaszner, 2013). Reports have shown that mice lacking the 
CRFR2 gene have increased anxiety-related behavior compared to WT mice 
suggesting CRFR2 activation may also serve to reduce anxiety (Kormos and Gaszner, 
2013). 
CRFR1 is widely expressed throughout the brain including the cortex, 
hippocampus, brainstem, and external globus pallidus (GPe), while CRFR2 is 
expressed mainly in the peripheral vasculature and the heart. Additionally, CRFR2 is 
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expressed in distinct subcortical structures in the brain. CRF binding sites are also 
found in the adrenal medulla, prostate, liver, kidney, gut, and testes (Bagosi et al., 
2006; Justice et al., 2008; Sztainberg et al., 2011; Tsigos and Chrousos, 2002; Van 
Pett et al., 2000). 
CRF is a member of a family of related peptides that include CRF-binding 
protein (CRF-BP), Urocortin I (UCN1), Urocortin II (UCN2), and Urocortin III (UCN3) 
(Fig.4) (Lewis et al., 2001; Reyes et al., 2001; Vaughan et al., 1995). UCN1 is 
expressed in the Edinger-Westphal nucleus (Vaughan et al., 1995). UCN2 expression 
is localized to the PVN and LC (Reyes et al., 2001). UCN3 expression is more robust 
being found in the perifornical area of the hypothalamus, BST, lateral septum, and 
amygdala (Li et al., 2002). CRF has 10-fold higher binding affinity for CRFR1 than 
CRFR2. In comparison to CRF, UCN1 has 6-fold higher affinity to CRFR1 and a 40-
fold higher affinity for CRFR2. UCN2 and UCN3 peptides are selective for CRFR2 
(Deussing and Wurst, 2005; Kormos and Gaszner, 2013). This evidence suggests that 
CRFR2 may be the endogenous receptor for UCN2 and UCN3. In addition, based on 
binding affinities, it becomes apparent that these related peptides may actually be 
cooperative agonists and serve related functions. Modulation of this network of 
peptides is not completely understood. 
CRF and UCN1 have related functions through their binding to CRFR1. One 
study found that UCN1 stimulated ACTH release from the rat anterior pituitary more 
robustly than CRF by activating CRFR1, both in vitro and in vivo (Asaba et al., 1998). 
Secondly, a report looking into hypothalamic GABA release and the effects on the 
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HPA-axis found that CRF and UCN1 have exactly the same effect (Bagosi et al., 
2012).  
However, UCN1 has been shown to have distinct functions. In studies using 
mouse models of Parkinson’s Disease (PD), both 6-OHDA (6-hydroxydopamine) and 
lipopolysaccharide (LPS) mediated nigrostriatal lesion models, UCN1 has been 
shown to be protective. In fact, when UCN1 was administered at the same time as the 
toxic agent, or as many as 7 days after the toxic agent, UCN1 is able to prevent and/or 
rescue dopaminergic neurons once damage has already been established 
(Abuirmeileh et al., 2007). UCN1 has been shown to mediate cytoprotection in cardiac 
tissue and in cultured neurons acting through CRFR1 (Brar, 2000; Choi et al., 2006; 
Scarabelli et al., 2002). Other reports have also pointed to a protective role for UCN1 
in the brain and periphery. How UCN1 performs this role through CRFR1 ligand 
activity is actively being researched. These studies also lead to the question to 
whether CRF has cytoprotective functions as well. It is likely that the unique actions 
of UCN1/CRFR1 activity stems from differential activation of secondary messenger 
networks (discussed below).  
UCN2 and UCN3 bind exclusively to CRFR2 therefore different actions than 
UCN1/CRFR1 signaling would be expected. A study found that	intracerebroventricular 
(ICV) administration of UCN2 produces an increase in amygdalar CRF concentrations 
after 5 minutes at both low and high concentrations. However, in this paradigm it took 
30 minutes for UCN2, and only at high concentrations, to increase hypothalamic CRF 
concentrations. The same result was found with ICV administration of UCN3. This 
indicates that UCN2 and UCN3 increase CRF concentrations both in the amygdala 
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and hypothalamus but in a time-dependent and dose-dependent manner through 
CRFR2. However, Cort levels were increased in a dose-dependent manner and not a 
time-dependent manner (Bagosi et al., 2013). In addition to this study, other groups 
have found dichotomous results on the effects of activation of CRFR2 on the HPA-
axis. Several groups have found that activation of CRFR2 stimulates the HPA-axis, 
but leads to anxiolytic effects in mice (Kishimoto et al. 2000; Bale et al. 2000). In 
contradiction, other groups have found that ICV administration of UCN2 or UCN3 
promotes anxiogenic behavior in rats	(Jamieson et al. 2006; Maruyama et al. 2007). 
To further illustrate the complexity of CRFR2 action, additional studies have reported 
that ICV administration of UCN2 or UCN3 have no effect on the HPA-axis or behavior	
(Pelleymounter et al. 2004; Zhao et al. 2007).	The difference between these studies 
is the does of CRFR2 agonist administered. Taking this evidence together, CRFR2 
action serves to be either stimulatory or inhibitory on the HPA-axis based on 
concentration of CRFR2 binding ligand (Bagosi et al., 2013).    	
CRF-BP binds both CRF and UCN1 with high affinity (Huising and Flik, 2005; 
Potter et al., 1991; Smith and Vale, 2006; Westphal and Seasholtz, 2006). CRF-BP 
was identified in maternal plasma where its function was found to inhibit HPA-axis 
activation as a result of elevated levels of placenta-derived CRF (Linton et al., 1988; 
McLean and Smith, 2001). CRF-BP dimerizes upon binding to CRF and removes CRF 
from blood. This CRF removal method serves to protect the maternal pituitary from 
elevated levels of CRF during pregnancy. In the periphery, CRF-BP is found in the 
liver and placenta. In the brain, CRF-BP is found in the cortex and subcortical limbic 
structures (Behan et al., 1995). Coincidentally, CRF-BP is highly expressed in the 
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pituitary. While the function of CRF-BP is not completely understood, an experiment 
provided evidence that recombinant CRF-BP reduces CRF-induced ACTH release 
from anterior pituitary cells in vitro (Westphal and Seasholtz, 2006). It is plausible that 
CRF-BP may bind CRF in the pituitary to lessen CRF receptor activity, reducing the 
stress response and Cort secretion. 
CRFR1 and CRFR2 are class 2B G-protein coupled receptors (GPCRs) which 
generally couple Gs and activate cAMP production in response to ligand binding. 
UCN2 and UCN3 minimally induce cAMP production when bound to CRFR2 (Hsu and 
Hsueh, 2001; Reyes et al., 2001). However, it has also been demonstrated that CRF 
receptors can activate other secondary messengers including inositol (1,4,5)-tri-
phosphate and Ca2+ through Gq-coupled activation of phospholipase C (PLC) 
(Dautzenberg and Hauger, 2002). The complexity of binding affinities and activation 
of secondary messenger pathways serves to illustrate the multitude of effects the CRF 
family of related-peptides signaling can have on the CNS and periphery. The focus of 
this work will be on CRF and CRFR1 signaling in the basal ganglia structure, the GPe 
which has robust expression of CRFR1. 
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Figure 1. The Hypothalamic-Pituitary-Adrenal (HPA)-axis.	 In response to a 
stressor, CRF is released from the PVN stimulating the release of ACTH from the 
anterior pituitary. ACTH travels through the systemic circulation to the adrenal cortex 
and stimulates the release of glucocorticoids, namely cortisol in humans and 
corticosterone in rodent. Glucocorticoids provide vital negative feedback to regulate 
the axis. Used with permission from Elsevier. License Number 4047070412252. 
Naughton, M., Dinan, T.G., Scott, L.V., 2014. Corticotropin-releasing hormone and the  
hypothalamic–pituitary–adrenal axis in psychiatric disease, in: Handbook of 
Clinical Neurology. pp. 69–91. doi:10.1016/b978-0-444-59602-4.00005-8 
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Figure 2. Detrimental effects of chronic stress on adipose tissue metabolism 
and bone mass. Solid lines indicate stimulation; dashed lines indicate inhibition. 
Journal of psychosomatic research by Leigh, Denis Reproduced with permission of 
ELSEVIER INC. in the format Thesis/Dissertation via Copyright Clearance 
Center. License Number 4042200487829.  
Tsigos, C., Chrousos, G.P., 2002. Hypothalamic–pituitary–adrenal axis, 
neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871. 
doi:10.1016/s0022-3999(02)00429-4 
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Figure 3. A simplified schematic representation of the central and peripheral 
components of the stress system, their functional interrelations and their 
relations to other central systems involved in the stress response. The CRH/ 
AVP neurons and central catecholaminergic neurons of the LC/NE system reciprocally 
innervate and activate each other. The HPA axis is controlled by several feedback 
loops that tend to normalize the time-integrated secretion of cortisol, yet 
glucocorticoids stimulate the fear centers in the amygdala. Activation of the HPA axis 
leads to suppression of the GH/IGF- 1, LH/testosterone/E2 and TSH/T3 axes; 
activation of the sympathetic system increases IL-6 secretion. Solid lines indicate 
stimulation; dashed lines indicate inhibition.  
Journal of psychosomatic research by Leigh, Denis Reproduced with permission of 
ELSEVIER INC. in the format Thesis/Dissertation via Copyright Clearance 
Center. License Number 4042200487829.  
Tsigos, C., Chrousos, G.P., 2002. Hypothalamic–pituitary–adrenal axis, 
neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871. 
doi:10.1016/s0022-3999(02)00429-4 
 
 
 
 
 
	  
	 18	
 
	  
	 19	
 
Figure 4. The mammalian CRF system and their receptors. CRF binds with high 
affinity to CRFR1 receptor, however it exerts very low affinity binding to CRFR2. UCN1 
has higher affinity for CRFR1 but also binds CRFR2. UCN2 and UCN3 bind with high 
affinity to the CRFR2 receptor only.  
Neuropeptides by CHURCHILL LIVINGSTONE. Reproduced with permission of 
CHURCHILL LIVINGSTONE in the format Thesis/Dissertation via Copyright 
Clearance Center. License Number 4042141167170.  
Kormos, V., Gaszner, B., 2013. Role of neuropeptides in anxiety, stress, and 
depression: from animals to humans. Neuropeptides 47, 401–419. 
doi:10.1016/j.npep.2013.10.014 
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The Basal Ganglia and the External Globus Pallidus  
	
The main network of subcortical structures that form the basal ganglia (BG) are 
the striatum (STR), the globus pallidus (GP), both external GP (GPe) and internal GP 
(GPi), the subthalamic nucleus (STN), and the substantia nigra: both the pars 
compacta (SNc) and the pars reticulata (SNr) (Albin et al., 1989; Francois et al., 1984; 
Yelnik et al., 1987). The STR is composed of projection neurons. Studies in rats have 
suggested that striatal projections form dense collateral projections with axons from a 
single neuron terminating in the GPe, GPi, and SNr (Graybiel et al., 1979; Grofová, 
1979). The STR receives input from all of the cortex (Kemp and Powell, 1970; Young 
et al., 1981). The primary neurotransmitter of the STR, GPe, GPi, and SNr is GABA, 
while the primary neurotransmitter of the STN is glutamate. The primary 
neurotransmitter released from the SNc is dopamine (Nakanishi et al., 1987; Smith 
and Parent, 1988).  The GPi and SNr are the major output nuclei of the BG.  
The classical connectivity of the basal ganglia is divided into a direct, motor 
promoting, and an indirect, motor inhibiting pathway which originate from distinct 
populations of striatal medium spiny neurons (MSNs) and project to different output 
structures, GPi or SNr (Fig.5) (Calabresi et al., 2014). However, current knowledge 
about the basal ganglia can be explained in an oversimplified, but useful, 
direct/indirect pathway model or in much greater detail that many have deemed too 
complex and controversial (Calabresi et al., 2014). 
There are as many hypotheses about the functions of the basal ganglia as 
groups who study its connectivity. In particular, the study of PD has had a major 
influence on the speculation of basal ganglia function. As parkinsonian patients have 
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difficulty initiating movement, this led to the hypothesis that the BG is involved in the 
automatic execution of learned motor movements (Albin et al., 1989; Turner and 
Desmurget, 2010). Overall, early studies into the functions of the BG were based on 
the dysfunction caused by disorders of the BG which are primarily motor oriented; PD, 
dystonia, and Huntington’s disease. Early studies using ablation of the output nuclei 
of the BG provided better patient outcomes in PD than ablation of BG inputs leading 
many to believe that dysfunction in BG circuits is more disruptive than eliminating the 
output of the BG in totality (Albin et al., 1989; Turner and Desmurget, 2010). This 
indicates that dysfunctional input to the STR may be the primary pathology that leads 
to disorders of the BG.  
The balance between the direct and indirect pathway is regulated by the 
opposing actions of dopamine on excitatory D1 receptors and inhibitory D2 receptors 
in the STR which receives differential dopaminergic innervation from the SNc. 
Importantly, these pathways do not function individually; both pathways are active 
simultaneously. Dopamine increases the activity of the direct pathway by D1 receptor 
excitatory activation while dopamine action on D2 inhibitory receptors reduces activity 
in the indirect pathway. The result of this particular innervation pattern is a reduction 
in the signaling from the output nuclei of the BG, the GPi and the SNr, manifesting as 
increased movement. Due to this circuitry, an increase in dopamine release from the 
SNc causes increased activity in the direct pathway resulting in increased movement 
while a decrease in dopamine release causes decreased activity in the direct pathway 
and increased activity in the indirect pathway resulting in decreased movement 
(DeLong and Wichmann, 2007). This model serves particularly well to describe the 
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manifestations of PD. As dopaminergic neuron loss occurs in the SNc, striatal 
dopamine depletion occurs leading to the motor symptoms of PD. Also, this model 
explains the efficacy of the surgical interventions and drugs used to reduce PD 
symptoms such as lesion of the GPi. By reducing the functioning of the GPi, less 
GABA is released to the thalamus allowing it to excite the motor cortex and increase 
movement. Additionally, treatment with L-dopa to replace lost dopamine increases the 
activity of the motor promoting, direct pathway. 
In the 1970s, it was thought that the BG integrated projections from limited 
portions of the cortex and projected this input through the thalamus to the motor cortex 
and supplementary motor area. This knowledge provided a mechanism by which 
movement could originate from functional cortical areas (DeLong and Wichmann, 
2007). More recent studies have suggested that the BG receives input from 
segregated cortical areas. This input terminates in specific basal ganglia territories 
which is then transmitted to the thalamus in a region specific pattern. Finally, the 
regional specificity of the thalamic connections project back to the same regions of the 
cortex from which the input originated (Alexander et al., 1986; DeLong and 
Georgopoulos, 2011; Kelly and Strick, 2004). These theories are partially based on 
experiments using rabies virus that revealed multisynaptic circuits generating 
segregated loops and lead to current models of the basal ganglia as segregated, 
specific cortico-subcortical loops (Kelly and Strick, 2004). For example, each of the 
BG nuclei have topologically organized motor, associative, and limbic circuits as 
revealed by imaging studies in humans (Fig.6) (Draganski et al., 2008; Lambert et al., 
2012; Lehéricy et al., 2004). If I take these new theories into account, disorders of the 
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BG are actually pathologies generated by aberrant neuronal activity throughout a 
specific loop (DeLong and Wichmann, 2007). As the complexities and functions of the 
BG are vast and debatable, I will focus on a specific nucleus of the BG located in the 
motor inhibiting, indirect pathway; the GPe. As mentioned, the GPe expresses high 
levels of the CRF receptor CRFR1 making it of particular interest in my examination 
of the stress response and CRF/CRFR1 signaling.  
For many years, the GPe was considered a homogenous GABAergic nucleus 
with the function of relaying inhibitory input from the STR downstream to the 
glutamatergic STN. In turn, the STN increases GPi activity leading to decreased 
movement (Albin et al., 1989; Alexander and Crutcher, 1990; Calabresi et al., 2014; 
Y. Smith et al., 1998; Wichmann and DeLong, 1996). However, in a historic 
experiment in awake macaque, DeLong found that the nucleus was not homogenous. 
He found that there are two subtypes of GABAergic neurons based on 
electrophysiological properties (DeLong, 1971). He found “high-frequency pausers” 
(~80%) which are neurons that fire at high frequency for long periods of time (~30 min) 
followed by brief periods of silence or low frequency firing. Also, he found “low-
frequency bursters” (~20%), which fire at low frequency for long periods of time 
followed by quick bursts of high frequency firing. This was the first evidence that there 
are two populations of GABAergic neurons in the GPe with distinct properties 
(DeLong, 1971). Today, the electrophysiologically distinct GPe neuronal subtypes are 
referred to as prototypic neurons closely resembling the “high-frequency pausers” and 
arkypallidal neurons, which resemble the “low-frequency bursters” (Abdi et al., 2015; 
Hernández et al., 2015; Mallet et al., 2012, 2008). 
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Prototypic neurons and arkypallidal neurons can be distinguished by their 
active and intrinsic membrane properties and in vivo responses to movement (Abdi et 
al., 2015; Dodson et al., 2015; Hernández et al., 2015; Saunders et al., 2016). Also, 
prototypic and arkypallidal neurons are derived from distinct neuronal lineages, 
express distinct molecular markers, and have distinct projection sites. Prototypic 
neurons are derived from the medial ganglionic eminence and express the 
transcription factor Nkx2.1 and the calcium binding protein parvalbumin (PV) (Flandin 
et al., 2010; Mallet et al., 2012). Arkypallidal neurons are derived from the lateral 
ganglionic eminence and express FoxP2, preproenkephalin (PPE), and Npas1 
(Dodson et al., 2015; Mallet et al., 2012; Glajch et al., 2016).  Interestingly, co-
expression of Npas1 and FoxP2 confers arkypallidal neuronal phenotype, while 
expression of Npas1 alone confers a prototypic neuronal phenotype (Abdi et al., 2015; 
Hernández et al., 2015). Finally, while Nkx2.1/PV prototypic neurons target the STN, 
arkypallidal neurons only innervate the STR  (Fujiyama et al., 2016; Mallet et al., 
2012).   
Motor deficits as manifested in PD that result from GPe dysfunction confirm its 
role in sensorimotor function (Anderson and Horak, 1985; Dodson et al., 2015; Jaeger 
et al., 1995; Jin et al., 2014; Kita, 2007; Mallet et al., 2016; Mitchell et al., 1987; Nambu 
et al., 2002; Obeso et al., 2006; Tachibana et al., 2011; Turner and Anderson, 2005; 
Yoshida and Tanaka, 2016). With a confirmed role in sensorimotor function, it is now 
believed that the GPe is a central nucleus in the BG (Fig.5) (Mallet et al., 2012; Mink, 
1996; Parent and Hazrati, 1995). Multiple experiments have been performed in 6-
OHDA lesioned PD rodent models to examine how aberrant GPe functioning effects 
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PD symptomology. Evidence has been provided by cell-labeled electrophysiology that 
PV prototypic neuron firing is preserved in PD models while Npas1 neuron firing is 
decreased (Abdi et al., 2015; Hernández et al., 2015). In fact, Npas1 neurons which 
primarily fall into the arkypallidal subtype, synapse on spiny projection neurons (SPNs) 
and interneurons (INTs) in the STR where they strengthen their connections in 6-
OHDA lesioned PD models (Glajch et al., 2016). This evidence provided the first 
insight that the GPe projecting upstream to the STR contributes to motor dysfunction 
in PD. From these evidence, the GPe has a central role in BG circuitry and is greatly 
altered in the dopamine depleted brain as a result of the progression of PD. 
Intriguingly, the GPe has robust expression of the CRF receptor CRFR1 suggesting 
that it may play a role in the stress response. In this work, I will explore the connectivity 
of the stress system with the GPe and the functional outcomes on behavior as a result 
of activation of CRFR1 expressing neurons in the GPe.  
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Figure 5. The hyperdirect, direct and indirect pathways and neural inhibition in 
the cortico–basal ganglia circuits.  
Nature Reviews Neuroscience by MACMILLAN MAGAZINES LTD.. Reproduced with 
permission of MACMILLAN MAGAZINES LTD. in the format Republish in a 
thesis/dissertation via Copyright Clearance Center. License Number 4047901506892. 
Jahanshahi, M., Obeso, I., Rothwell, J.C., Obeso, J.A., 2015. A fronto–striato– 
subthalamic–pallidal network for goal-directed and habitual inhibition. Nat. Rev. 
Neurosci. 16, 719–732. doi:10.1038/nrn4038 
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Figure 6. The main functional subdivisions in the sensorimotor, associative and 
limbic cortico–striatal circuits. These multiple loops suggest that the GPe map play 
a role in all of these complex behaviors (A) Motor circuit (B) Associative Circuit. (C) 
Limbic circuit.  
Nature Reviews Neuroscience by MACMILLAN MAGAZINES LTD.. Reproduced with 
permission of MACMILLAN MAGAZINES LTD. in the format Republish in a 
thesis/dissertation via Copyright Clearance Center. License Number 4047901506892. 
Jahanshahi, M., Obeso, I., Rothwell, J.C., Obeso, J.A., 2015. A fronto–striato– 
subthalamic–pallidal network for goal-directed and habitual inhibition. Nat. Rev. 
Neurosci. 16, 719–732. doi:10.1038/nrn4038 
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Computational and Theoretical Neuroscience aspects of the External Globus 
Pallidus 
	
The BG has a myriad of proposed (theoretical) functions in behavior and 
cognition. One function is action selection and the GPe is believed to play a major role 
in this behavior (Berns and Sejnowski, 1998; Bogacz et al., 2016; Cools, 1980; Denny-
Brown and Yanagisawa, 1976; Hikosaka, 1994; Mink, 1996; Redgrave et al., 1999; 
Robbins and Brown, 1990; Schultz, 2001; Wickens, 1997, 1993). A “selection 
problem” occurs when two or more competing behavior programs seek access to a 
restricted or limited network such as the BG (Redgrave et al., 1999). The selection of 
one behavior over another is sometimes referred to as behavior switching (McFarland, 
1989; Redgrave et al., 1999). When multiple actions can be taken, the one with the 
greatest salience should be selected. For instance, if an animal has a choice between 
eating, drinking, or escaping a threat, escaping the threat should be able to cancel the 
other actions as it is the most salient for survival. All three behaviors require the motor 
system which is a limited resource. A mechanism to inhibit the less salient behaviors 
must exist. In this case, the mechanism is the ability of the BG to inhibit actions or 
behaviors.   
Computational models have provided evidence as to how the BG could select 
an action in the fastest way possible with the greatest accuracy. These models further 
suggests that a single nuclei in the BG, the GPe, must calculate a function of its inputs 
(Bogacz et al., 2016). 
Goal-directed behavior is a type of action or behavior an animal can select.  
Goal-directed behaviors are intentional, considered, and sensitive to the value of the 
prospective goal (Dickinson, 1985).  In contrast, the opposite of goal-directed behavior 
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is a response automatically triggered by some stimuli. This is referred to as habitual 
behavior (Gillan and Robbins, 2014). Animals use both reflective (goal-directed) and 
reflexive (habitual) action selection (Dolan and Dayan, 2013; Seger and Spiering, 
2011). For goal-directed behaviors, it is critical that an animal is able to select the 
appropriate action and learn to modify it irrespective of whether it is motor or non-
motor in nature (Yttri and Dudman, 2016). Interestingly, goal-directed behavior suffers 
in times of stress (Schwabe and Wolf, 2009). It is possible that this decrease in goal-
directed behavior may be mediated directly by CRF actions on the GPe as the stress 
response may be the most salient action to select, allowing behavioral switching from 
goal-directed to habitual or automatic behavior.  
In a recent computational model, the STN-GPe network regulates the 
competition between actions and guarantees that the most beneficial action is 
selected. The GPe needs to provide GABAergic feedback to the STN in order to 
compute the optimal action. It is postulated that prototypic and arkypallidal neurons 
that make up the GPe network could compute the function required for optimal action 
selection. The model calculates that the GPe will receive input from the STN even 
when the STN does not receive excitatory input.  
Recent modeling of the connectivity in the STN-GPe network suggests that 
both prototypic and arkypallidal neurons receive input from the STN. The model 
considers both GPe neuronal subtypes, prototypic and arkypallidal neurons. The 
micro circuitry of the GPe processes the input from the STN allowing for optimal action 
selection. The STR provides input to both prototypic and arkypallidal GPe neurons. 
However, the model postulates that prototypic neurons receive more input from the 
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STR than arkypallidal neurons. Ultimately, the model proposes that the GPe itself, 
based on the different electrophysiological properties of prototypic and arkypallidal 
neurons and their projections sites, is able to calculate optimal action selection 
(Bogacz et al., 2016).  
Although computational modeling is a very beneficial tool to make predictions 
in the study of theoretical and computational neuroscience, the caveats that it may or 
may not be reproducible in vivo exists. However, this evidence bolsters my 
investigation into CRFR1 activity in the GPe because the possibility of optimal action 
selection in the stress response when I explore activation of CRFR1 expressing 
neurons exists. The computational modeling provides an intellectual framework for 
conceptualizing how CRF stress signaling could mediate behavior switching through 
its novel actions on the GPe. 
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Opening Remarks 
	
Interestingly, CRFR1 is highly expressed in the GPe but no function has been 
defined (Justice et al., 2008). CRF is the stress peptide that initiates the stress 
response. The question is raised as to why the receptor responsible for the anxiogenic 
effects of CRF is located in the GPe. One study, found that knockdown of CRFR1 by 
siRNA injection directly into the GPe leads to an increase in anxiety-related behavior 
therefore concluding that the GPe may have an anxiolytic role in behavior (Sztainberg 
et al., 2011). This is in direct opposition of the known function of CRF/CRFR1 
signaling. As has been discussed throughout this introduction, BG functions are not 
clear and many have been proposed.  Through this work, I will provide evidence 
that the GPe has a role in anxiety-related behavior. Assigning a new role or circuit of 
the BG to the expression of complex behaviors advances our knowledge of the BG as 
more than merely a motor-mediating network. My novel findings demonstrate that one 
subtype of neuron in the GPe that expresses CRFR1 modulates anxiety-related 
behavior as part of an integrated stress response. Also, I find that neurons that 
express CRFR1 are exclusively prototypic. As the GPe has robust expression of 
CRFR1, experiments were performed to understand how CRF circuits may impinge 
on BG functioning to bias motor output or action selection in the stress response.  
 In this dissertation, I document the description of CRFR1 expressing neuron’s 
electrophysiological response ex vivo in acute brain slices to CRF application. I also 
systematically characterize the molecular phenotype of CRFR1 expressing neurons. 
I demonstrate the connectivity of CRF neurons to CRFR1 expressing neurons in the 
GPe and evaluate the local connectivity within the GPe. Lastly, I explore the functional 
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role of CRFR1 neuron activation, using a chemogenetic strategy, in the GPe on 
anxiety-related behavior while assaying mouse behavior in a variety of anxiety-related 
behavior and movement paradigms.  
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Experimental Procedures 
	 36	
Animal care and genetic crosses 
	
Mice were housed up to five per cage with ad libitum access to food and water 
in a pathogen-free facility with a 12h light/dark cycle. All procedures were performed 
in accordance with the National Institutes of Health guidelines and with the approval 
of the University of Texas Health Science Center at Houston Institutional Animal Care 
and Use Committee (IACUC).  Male and female mice aged 12-16 weeks were used 
for viral tracing and immunohistochemistry experiments. Ex vivo electrophysiological 
recordings were performed in 4-8 week old animals.  Behavioral experiments were 
performed using 12-16 week old male mice. The BAC transgenic mouse line, CRFR1-
GFP, was used to accurately identify CRFR1 expressing neurons for 
immunohistochemistry and electrophysiological recordings. In brief, an approximately 
500-bp fragment of genomic DNA directly upstream of the ATG start codon in CRFR1 
was amplified by PCR and sub-cloned in a shuttle vector containing eGFP with a polyA 
encoding sequence. A 500-bp DNA sequence within the first intron of CRFR1 was 
sub-cloned into the shuttle vector. The modified shuttle vector was transformed into 
Escherichia coli containing the BAC rp23-4B21. This BAC contained the CRFR1 
genomic locus. BAC DNA from a single E. coli colony was isolated, and PCR was 
performed to verify that the shuttle vector inserted into the CRFR1 locus by 
homologous recombination. DNA that showed correct recombination was isolated and 
injected into single-cell mouse oocytes. A single mouse carrying the BAC was 
obtained (Justice et al., 2008). A CRFR1-Cre-2A-tdtomato BAC transgenic mouse line 
was generated using a similar strategy to the CRFR1-GFP BAC transgenic mouse 
line. Briefly, a BAC (rp23-239f10; Children’s Hospital Oakland Research Institute) 
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containing the entire genomic locus of CRFR1 was modified using recombineering 
(Chan et al., 2007; Liu et al., 2003). A cassette encoding iCre-p2A-tdtomato-PA was 
inserted in the first exon at the site of the ATG start codon for CRFR1. Modified BAC 
DNA was purified and injected in single celled oocytes to generate transgenic offspring 
(Genetically Engineered Mouse Core, Baylor College of Medicine, Houston). Three 
independent transgenic lines were recovered, of which one (CRFR1-cre) had the best 
co-localization of cre/tdtomato with CRFR1-GFP. In situ hybridization was performed 
and confirmed that iCre is expressed in the same cells as Crfr1 in the Globus Pallidus. 
CRFR1-cre mice were used for viral tracing and behavioral experiments. The BAC 
transgenic Npas1-iCre-2A-tdtomato mouse line herein referred to as Npas1-cre has 
been previously characterized and validated (Hernández et al., 2015). CRH-IRES-
CRE (CRF-cre; (Chen et al., 2015)) was obtained from The Jackson Laboratory and 
crossed to a floxed tdtomato reporter line (Ai9; (Madisen et al., 2010)) to express the 
fluorescent reporter tdtomato in CRF neurons and fibers. 
Tissue preparation, immunohistochemistry, and cell quantification 
	
Mice were deeply anesthetized by IP injection of tribromoethanol (125 mg/kg 
from a stock solution of 1.25% v/v) and transcardially perfused with saline followed by 
4% paraformaldehyde. Brains were removed and post-fixed in the same fixative for 
12 h at 4℃. Brains were then equilibrated in 30% sucrose, and 30 𝜇m coronal sections 
were prepared using a frozen sliding microtome. Free floating sections were washed 
in PBS and incubated overnight with antibodies diluted in PBS + 0.4% Triton X-100 
with 2% normal donkey serum. Antibodies used were as follows: goat anti-GFP 
(1:1000, Rockland), rabbit anti-TTF-1 (also known as Nkx2.1; 1:1000, EMD Millipore), 
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rabbit anti-NeuN (D3S3I,1:1000, Cell Signaling Technologies), mouse anti-
Parvalbumin (1:1000, EMD Millipore), rabbit anti-Npas1 (Npas1-3, 1:1000, gift from S. 
Chan), rabbit anti-FoxP2 (1:1000, EMD Millipore), rabbit anti-Synapsin-1 (D12G5, 
1:1000, Cell Signaling Technologies), rabbit anti-c-FOS (1:20,000, Synaptic 
Systems), and rabbit anti-CRF (rc70, 1:2000, gift from W. Vale). Following incubation, 
tissue sections were washed in PBS and treated with the appropriate secondary for 2 
h, washed in PBS, and mounted on gelatin-coated slides. Images were obtained on a 
Leica TCS SP5 confocal microscope. All images presented are max projections. In 
CRFR1-GFP mice, colocalization of GFP and the molecular marker of interest was 
quantified by manual counting of 3 images per brain from n=3-5 mice at different 
rostro-caudal levels of the GPe. Quantification was averaged over all sections without 
separation based on rostro-caudal distribution of neurons expressing molecular 
markers as previously described (Dodson et al., 2015). For tracing experiments, half 
of the brain sections were mounted for quantification of starter and traced cells using 
an epifluorescent microscope. Staining of starter and traced cells was performed on 
brain sections not used for connectivity ratio quantification. 
Stereotaxic injections of adeno-associated virus 
	
Mice were deeply anesthetized with isoflurane and secured in a mouse 
stereotaxic frame. Under aseptic conditions, a minimal incision was made to expose 
the skull. A small craniotomy was made using a drill at coordinates 0.0 mm rostral, ± 
2.1 mm lateral, and -3.8 mm ventral to bregma. Injections were made using a Nanoject 
II (Drummond Scientific) with a pulled glass pipette at a rate of 50 nL/min. Following 
completion of injection, the pipette was left in place for 5 minutes to allow for 
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absorption of the virus before being removed.  For viral tracing, I injected 50 nL of a 
1:1 mixture of Cre-dependent AAVs carrying FLEXed TVA-mCherry and FLEXed 
Rabies G (AAV-EF1a-FLEX-TVA-mCherry, AAV-CA-FLEX-G obtained from the UNC 
viral vector core; (Watabe-Uchida et al., 2012). After 2 weeks, I delivered 200 nL of 
Pseudotyped rabies virus (AAV-EnvA-SADΔG-eGFP supplied by Dr. Ben Arenkiel; 
(Wickersham et al., 2007)) in the same location. After 5 days, I made an icv injection 
of colchicine (0.3 mg/kg solution in ddH2O) to enhance CRF staining of cell bodies. 
Mice were sacrificed at 7 days post-injection of PTRV. For DREADD experiments, I 
made 100 nL bilateral injections of Cre-dependent Gq-coupled DREADD (AAV-hSyn-
DIO-hM3D(Gq)-mCherry obtained from the UNC Viral Vector Core; (Armbruster et al., 
2007)) into the GPe (0.0AP, ± 2.1ML, -3.8DV to bregma). Mice were returned to their 
home cage for 2 weeks before initiation of behavioral testing to allow for expression 
of DREADDs from the virus.  
Slice preparation 
	
Parasagittal slices (250 μm) were obtained from male and female CRFR1-GFP 
animals, aged 4-8 weeks. All procedures followed were in accordance with National 
Institutes of Health guidelines and approved by the University of Texas Health Science 
Center at Houston animal welfare committee. Animals were anesthetized using 
isoflurane, decapitated, and their brains were quickly extracted and placed into ice-
cold solution saturated with 95% O2–5% CO2, and consisting of the following (in mM): 
212 sucrose, 2.5 KCl, 1.25 NaH2PO4, 10 MgSO4, 26 NaHCO3, 11 glucose, and 0.5 
CaCl2. Slices were prepared using a vibratome (Leica VT1200S) and then incubated 
at 34°C for 50 min in artificial cerebrospinal fluid (ACSF) containing the following (in 
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mM): 126 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 10 glucose, 2 CaCl2, and 1 MgCl2 
(saturated with 95% O2–5% CO2). Slices were then kept at room temperature to 
preserve health until used for experiments. 
Electrophysiological recordings 
	
Recordings were performed at 31–33°C using an in-line heater (Warner 
Instruments) while perfusing the recording chamber with ACSF. Neurons were 
visualized using infrared differential interference contrast using an Olympus BX51WI 
microscope and an IR-1000 camera (Dage-MTI). GFP+ cells were identified under 
fluorescence using an X-Cite 120Q light source. Loose-patch voltage-clamp 
recordings from CRFR1-GFP+ and GFP- GPe neurons were obtained with glass 
pipettes (3–5 MΩ) filled with ACSF. Seal resistance was maintained between 40–70 
MΩ. To minimize perturbations of the firing rate of the recorded neuron, command 
voltage was continuously adjusted during the recordings to maintain a holding current 
near 0 pA (Perkins, 2006). Experiments were done in the presence of DNQX (10 µM), 
D-APV (25 µM), and Picrotoxin (50 µM) to block AMPARs, NMDARs, and GABAARs, 
respectively. DNQX and Antalarmin were obtained from Tocris Bioscience. Picrotoxin 
and D-APV were obtained from R&D Systems. CRF was kindly provided by J. Rivier. 
All other chemicals were obtained from Sigma-Aldrich. 
Data acquisition and analysis 
	
Data were acquired using a Multiclamp 700B amplifier (Molecular Devices), 
filtered at 6–10 kHz, and digitized at 20 kHz with a 16-bit analog-to-digital converter 
(Digidata 1440A; Molecular Devices). Recordings were acquired using Clampex 10.3 
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software (Molecular Devices) and analyzed using custom macros written in Igor Pro 
(Wavemetrics). 
Calculation of Pseudotyped Rabies Virus “Connectivity Ratio” 
	
Brain sections were imaged and “starter” neurons were identified by their co-
expression of TVA-mCherry and GFP indicating a cell competent to transmit the rabies 
virus. Traced neurons were identified by their expression of GFP in the absence of 
TVA-mCherry. A calculation was made of total traced neurons in a given region 
divided by the total starter neurons in the GPe to give the “connectivity ratio” used to 
compare the relative cellular input from canonical and novel brain regions that project 
and synapse in the GPe. This “connectivity ratio” allowed for the comparison of GPe 
inputs between CRFR1-cre and Npas1-cre animals. 
Behavioral Testing 
	
Prior to behavioral testing, mice were placed in the behavior room and allowed 
to acclimate for 1 h. At the beginning of testing, 2 mg/kg of Clozapine-N-oxide (CNO) 
was IP injected, and the mice were returned to their home cage for a period of 10 min 
to allow for the activation of DREADDs. Mice were tested on the Light-Dark Transfer 
(LDT) test, Marble Burying task, and the Open Field Assay (OFA). All parameters of 
movement were tracked by a computer system and analyzed post-hoc. 
          OFA. Mice were placed in the center of 36 cm2 square open field and allowed 
to move freely for 30 min.  Their field position was tracked using a photo beam system 
(Kinder Scientific). The maze was divided into a surround zone (9 cm. bordering the 
edge of the field on all sides), and a center zone (center 18 cm. square field). I 
analyzed total distance traveled, center distance traveled, surround distance traveled, 
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center time, and surround time. I used the ratio of center distance to total distance 
traveled as a measurement of anxiety-related behavior to normalize for movement 
differences within each mouse, to minimize the impact of changes in total movement 
on anxiety scores (Bale et al., 2000). 
           LDT. Mice were placed in the OFA with a Plexiglass insert dividing the arena 
into a dark half and a light half. The light and dark regions were separated by a cut 
out allowing the mouse to pass freely from one side of the arena to the other. Mice 
were placed on the dark side at the beginning of the 10 min testing period. I measured 
total distance traveled, light distance, dark distance, number of transfers between 
regions, and time spent in each region. I quantified anxiety-related behavior using light 
entries and total time spent in the light (Bale et al., 2000). 
Marble Burying. Mice were placed in a Plexiglass cage of the same 
dimensions as their home cage filled with 1 liter of alpha-dri bedding. 10 marbles were 
placed in the cage spaced evenly apart on the bedding. The testing period lasted for 
15 minutes. At the completion of testing, only marbles that were completely buried 
were counted as buried. An increase in the total number of marbles buried is 
interpreted as an increase in anxiety-related behavior (Kedia and Chattarji, 2014). 
Post-hoc analysis of viral injections 
	
Immediately following the completion of behavior analysis, mice were perfused, 
brains sectioned and mounted for analysis using an epifluorescence microscope to 
determine the accuracy and relative diffusion of viral injections. Mice were excluded 
from the study (~10) if neurons outside of the target region (GPe) expressed 
DREADD-mCherry. In some cases, animals were given injections of CNO (2 mg/kg 
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IP) 2 hours before perfusion and brain slices were stained for the immediate early 
gene cFOS to verify CNO activation of DREADD expressing neurons. No mice were 
excluded from this analysis.  
Statistics 
	
For behavioral experiments (control vs. DREADD, same genotype), a two-
tailed Student’s t-test was used to determine significance in GraphPad Prism 5.04. 
For slice electrophysiology, a two-tailed Student’s t-test was used. The results are 
presented as mean ± SEM. For all figures p<0.05 - *, p<0.01 - **, and p<0.001 - ***. 
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CRFR1-GFP Neuronal Electrophysiological Profile in Response to CRF
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In Brief 
	
 There have been no functional studies performed to validate GFP as a proxy 
for CRFR1 expression in the GPe in the BAC transgenic CRFR1-GFP mouse. CRFR1 
activation by the stress-responsive neuropeptide CRF is accepted to be excitatory, 
however sex difference studies in CRF/CRFR1 signaling suggest this doctrine may be 
weakening. One study found that serotonergic neurons in female mice have reduced 
excitability and a decreased response to CRF compared to males suggesting that 
CRF may not always be excitatory when considering both males and females. In 
addition, it was found that CRF infusion into the dorsal raphe (DR) in male mice 
increases cFos, an immediate early gene whose expression is indicative of neuronal 
activation. While CRF activates neurons in the DR of males, infusion of CRF into the 
DR of female mice decreases cFos, indicating the absence of neuronal activation 
(Bagosi et al., 2012; Howerton et al., 2014).  
 This is the first study to record the electrophysiological response of CRFR1+ 
GPe neurons to CRF application. In order to provide evidence that GFP can report the 
expression of CRFR1 and that CRF is excitatory through CRFR1 in the GPe, we 
performed electrophysiological recordings from GFP+ neurons in the GPe of CRFR1-
GFP mice while infusing a single concentration of CRF into the recording chamber. 
We performed simultaneous paired recordings. Using paired recordings provided an 
unparalleled control as both GFP+ and GFP- neurons are being recorded 
simultaneously as CRF was applied to the same brain slice. Our results indicate that 
100% of the CRFR1-GFP+ neurons respond to bath application of CRF with a robust 
increase in firing. 100% of the paired neurons that did not express GFP did not 
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respond to bath application of CRF. The excitatory effect of CRF on GFP+ neurons 
was blocked using the small molecular, non-peptide CRFR1-specific antagonist 
Antalarmin, verifying that the effects of CRF were in fact mediated through CRFR1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 47	
Results 
	
 To investigate the impact of CRF on GPe neuron excitability, we prepared 
parasagittal brain slices from CRFR1-GFP animals and performed simultaneous 
loose-patch recordings from neighboring GFP+ and GFP- neurons in the GPe. We 
blocked fast glutamatergic and GABAergic synaptic transmission with 10 μM DNQX, 
25 μM AP5, and 50 μM Picrotoxin to examine the effects of CRF on autonomous 
activity of GPe neurons. Following bath application of 30 nM CRF, GFP+ neurons 
displayed a significant increase in mean firing rate (47.56 ± 6.07 Hz vs. 25.84 ± 8.86 
Hz, n=5, t(4)=2.88, p<0.05, Fig.7 A top trace) while simultaneously recorded GFP- 
neurons were unaffected by the application of CRF (12.01 ± 3.85 Hz vs. 12.35 ± 3.88 
Hz, n=5, t(4)=0.34, p=0.75, Fig.7 A bottom trace). To ensure that the observed 
response to CRF in GFP+ cells was mediated by CRFR1, we recorded from GFP+ 
cells in the presence of the selective CRFR1 non-peptide antagonist Antalarmin 
(Webster, 1996). In the presence of 1 μM Antalarmin, CRF application did not increase 
the mean firing rate of GFP+ neurons (21.99 ± 7.61 Hz vs. 19.02 ± 6.06 Hz, n=5, 
t(4)=0.92, p=0.41, Fig.7 B). These data confirm that GFP expression in CRFR1-GFP 
mice reports functional expression of CRFR1 in the GPe. 
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Figure 7. CRF increases firing rates in CRFR1 neurons. (A) Left, Simultaneous 
loose-patch voltage clamp recordings from neighboring GFP+ (green traces) and 
GFP- (grey traces) neurons (<100 µm intersomatic distance). Bath application of 30 
nM CRF led to an increase in firing in the GFP+ neuron, but not in the GFP- neuron. 
Right, Quantification of CRF-induced changes in firing rates of GFP+ (top) and GFP- 
neurons (bottom). All data were recorded from mixed pairs (n=5 pairs). (B) 
Representative loose-patch recording from a GFP+ neuron in the presence of 1µM 
Antalarmin in the bath solution. Bath application of 30 nM CRF did not lead to an 
increase in firing frequency. Right, Quantification of CRF-induced changes in firing 
rates of GFP+ neurons recorded in the presence of Antalarmin. n=5 neurons. Note: 
These experiments and creation of the figure were done in collaboration with Rajan 
Dasgupta and Michael Beierlein, PhD who have provided permission to use the figure.    
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Conclusions 
	
 These experiments provided the necessary data to illustrate that GFP 
fluorescence in CRFR1-GFP mice faithfully reports CRFR1 expression. In our 
experimental paradigm, we recorded from 5 pairs of GFP+ and GFP- neurons while 
performing bath application of CRF. We observed an increase in firing in response to 
CRF in all 5 GFP+ neurons, and the absence of a response in all 5 of the GFP- 
neurons. Using the CRFR1-specific antagonist, we also verified that the observed 
increase in the mean firing rate of GFP+ CRFR1 expressing neurons was mediated 
through CRFR1. In sum, the CRFR1-GFP mouse is a viable, reliable tool to visualize 
CRFR1 expression until a dependable and cost effective antibody is produced. 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Note: These experiments were performed in collaboration with the Beierlein Lab, 
McGovern Medical School, Houston, TX, USA 
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CRFR1 Expressing Neurons in the GPe are Prototypic
	 52	
In Brief 
	
The GPe has recently been shown to contain highly heterogeneous cell types 
that arise from distinct neural lineages and have differing afferent and efferent 
connections (Abdi et al., 2015; Dodson et al., 2015; Glajch et al., 2016; Hegeman et 
al., 2016; Hernández et al., 2015; Mallet et al., 2012; Saunders et al., 2016). 
Electrophysiological recordings in awake macaque provided the first insights into this 
diversity. Two classes of neurons were identified: “high-frequency pausers” and “low-
frequency bursters”. One class of neuron fired regularly at high-frequency with brief 
periods of silence, while the second class remained relatively silent but had the 
capability to fire at high-frequency for brief periods of time (DeLong, 1971). Due to the 
highly dynamic electrophysiological properties of GPe neurons, further refinement of 
neuronal subtypes necessitates discriminating the neuronal types based on mRNA 
expression profiles. 
Based on firing patterns, two terms have been assigned to the neuronal classes 
Delong discovered: prototypic and arkypallidal. Prototypic neurons most closely 
correspond to the “high-frequency pausers,” and arkypallidal neurons are analogous 
to the previously observed “low-frequency bursters” (DeLong, 1971; Mallet et al., 
2012). These neurons can be discriminated by their expression of molecular markers 
and major projection sites. Prototypic neurons are derived from the medial ganglionic 
eminence and primarily project to the subthalamic nucleus (STN). They uniquely 
express the transcription factor Nkx2.1 and/or the calcium binding protein Parvalbumin 
(PV). Arkypallidal neurons are derived from the lateral ganglionic eminence and are 
defined by their expression of the transcription factor FoxP2. All (>99%) FoxP2 
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neurons co-express the transcription factor Npas1. Arkypallidal neurons that express 
Npas1 project exclusively to the STR (Abdi et al., 2015; Flandin et al., 2010; Mallet et 
al., 2012; Nóbrega-Pereira et al., 2010). The robust expression of CRFR1 in the GPe 
raises the intriguing question of whether CRFR1 expression is restricted to a particular 
neuronal subtype (Justice et al., 2008; Sztainberg et al., 2011). Moreover, why is the 
CRF receptor, which partly mediates anxiogenesis, abundantly expressed in the GPe? 
Activation of one neuronal subtype in the GPe by CRF/CRFR1 signaling may provide 
insight into the role of the BG in stress and stress-related behaviors. To determine 
whether CRFR1 expression is restricted to one subtype or is ubiquitously expressed 
in the GPe, I performed immunofluorescent labeling for prototypic and arkypallidal 
neuronal markers in BAC transgenic CRFR1-GFP mice. In CRFR1-GFP mice, it has 
been validated that GFP expresses in the same pattern as CRFR1 in the GPe (Justice 
et al., 2008; Sztainberg et al., 2011). Using an anti-GFP primary antibody as a proxy 
for CRFR1 expression, I examined co-expression of CRFR1 with prototypic and 
arkypallidal neuronal markers to determine which subtypes of neurons express 
CRFR1 by immunofluorescence. My technique allowed me to reveal that CRFR1 is 
expressed exclusively by prototypic neurons.      
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Results 
	
I performed immunofluorescent labeling in CRFR1-GFP mice to systematically 
characterize the prototypic or arkypallidal identity of CRFR1 neurons in the GPe. I 
used the neuronal marker NeuN to determine that CRFR1 is expressed by 61.1 ± 
4.72% of GPe neurons (Fig.8 A-C) (Fields et al., 2015). 86.0 ± 5.18% of CRFR1-GFP 
neurons co-express the prototypic neuron marker Nkx2.1, while 72.6 ± 0.93% of 
Nkx2.1 neurons co-express GFP (Fig.9 A-C) (Mallet et al., 2012). I observed that 53.3 
± 3.20% of the CRFR1-GFP neurons in the GPe express PV consistent with previous 
reports (Fig.9 D-F) (Sztainberg et al., 2011). Of great interest, nearly all PV neurons 
(98.6 ± 0.44%) express CRFR1-GFP (Fig.9 N). A subpopulation of Nkx2.1+ GPe 
neurons co-expresses PV (Abdi et al., 2015; Dodson et al., 2015; Hernández et al., 
2015). My results indicated that 36.3% ± 2.35% of CRFR1-GFP+ neurons express 
both Nkx2.1 and PV (Fig.10 A-D). I found that no CRFR1-GFP neurons express the 
arkypallidal neuronal marker FoxP2 (Fig.9 J-L) (Abdi et al., 2015; Dodson et al., 2015). 
However, a small population of CRFR1-GFP+ neurons expresses Npas1 (6.49% ± 
1.10%), while roughly 10% of Npas1+ neurons co-express CRFR1-GFP (Fig.9 G-I).  
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Figure 8. Quantification of CRFR1-GFP in the GPe. (A) CRFR1-GFP expression 
in the GPe. (B) Immunofluorescent labeling of the neuronal marker NeuN. (C) 
Merged image showing the overlay between CRFR1-GFP and NeuN. The arrows 
indicate neurons that do not express CRFR1-GFP. Scale Bar = 100 µm (D) 61% of 
the GPe expresses CRFR1-GFP while 39% does not. 
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Figure 9. Molecular characterization of CRFR1+ neurons in the GPe. CRFR1-
GFP brain sections were stained for Nkx2.1 (A-C), PV (D-F), Npas1 (G-I), and FoxP2 
(J-L). The majority of CRFR1 positive GPe neurons are also positive for Nkx2.1 and/or 
PV. A small number of CRFR1 cells are Npas1+ (G-I), and no FoxP2 neurons express 
CRFR1 (J-L). (M) Quantification of the percent overlap of each molecular marker with 
GFP. (N) Quantification of the percent of each defined cell type that co-expresses 
CRFR1-GFP. Arrows indicate examples of double labeled cells. Arrowheads indicate 
examples of singly labeled cells. Scale bar = 50 µm.  
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Figure 10. Co-expression of Nkx2.1 and PV in CRFR1-GFP cells. (A) CRFR1-GFP 
expressing neurons in the GPe. (B) Immunofluorescent labeling of Nkx2.1. (C) 
Immunofluorescent labeling of PV in the GPe. (D) Merged image showing that Nkx2.1 
and PV are co-expressed in some CRFR1-GFP cells. Scale Bar = 50 µm. 
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Conclusions 
	
 Although many antibodies to CRFR1 have been prepared and used by various 
groups, none have proved reliable (Justice et al., 2008). The BAC transgenic CRFR1-
GFP mouse (see Experimental Procedures) became a necessity to provide a proxy 
for CRFR1 expression through GFP fluorescence. Immunohistochemical data 
obtained by these experiments provide evidence that CRFR1 is expressed exclusively 
by prototypic neurons (Nkx2.1 and/or PV), and is absent from arkypallidal neurons 
(FoxP2). I observed a small proportion of CRFR1-GFP neurons that were positive for 
Npas1. All (>99%)  FoxP2+ neurons are arkypallidal neurons and express Npas1, 
however Npas1 co-expression with Nkx2.1 and PV has been observed (Abdi et al., 
2015; Hernández et al., 2015). This fact leads one to draw the conclusion that Npas1 
neurons are arkypallidal. However, a distinction exists between Npas1+ neurons that 
co-express the prototypic neuronal markers Nkx2.1 and/or PV and Npas1+ neurons 
that co-express the arkypallidal neuronal marker FoxP2. Therefore, Npas1 cannot be 
used to neatly discriminate between prototypic and arkypallidal neurons (Dodson et 
al., 2015). My data indicates that CRFR1-GFP does not co-express with FoxP2, 
therefore the CRFR1-GFP+/Npas1+ neurons I observed are prototypic further 
bolstering my conclusion that CRFR1 is expressed exclusively by prototypic neurons 
(Abdi et al., 2015; Hernández et al., 2015). Although Npas1 cannot be used to 
discriminate between prototypic and arkypallidal neurons, Npas1 is an excellent 
marker of neurons that form the pallidostriatal pathway (Abdi et al., 2015; Glajch et 
al., 2016). My observation that CRFR1 is expressed by prototypic neurons that 
primarily make up the pallidosubthalamic tract suggests that the small proportion of 
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STR targeting CRFR1-GFP+/Npas1+ neurons allows CRF/CRFR1 signaling to have 
distinct and disparate functions based on activation of GPe neuronal subtypes.  
It is well documented that the GPe is involved in processing sensorimotor 
information and recent literature has provided evidence that the GPe projects to all 
basal ganglia nuclei and is not an isolated member of the motor inhibiting indirect 
pathway (DeLong, 1971; Glajch et al., 2016; Mallet et al., 2012; Obeso et al., 2006). 
The primary input to the GPe is the striatum (STR) and STR neurons are known as 
medium spiny neurons (MSNs). Output of the STR can be divided into two main 
projections that have opposing effects on movement, the direct and indirect pathways 
(DeLong, 1990). Direct pathway MSNs express the dopamine excitatory receptor D1 
and project primarily to the pars reticulata of the substantia nigra (SNr). In addition, 
these neurons send input to the internal globus pallidus (GPi), known as the 
entopeduncular nucleus (EP) in mouse. Indirect pathway MSNs express the dopamine 
inhibitory D2 receptor and send their projections to the GPe. Not only are these 
pathways differentiated based on the expression of dopamine receptor subtypes and 
projection sites, but they have opposing effects on movement, reinforcement, and 
reward-related behavior (Ferguson et al., 2011; Kravitz et al., 2012; Lobo et al., 2010; 
Wall et al., 2013).  
The GPe mimics the organization of the STR with two neuronal classes that 
express CRFR1 in a distinct pattern and have different projection sites, similar to the 
direct D1 and indirect D2 pathways in the STR. It is reasonable to draw a parallel 
between the STR and the GPe. The GPe’s two neuronal pathways, the prototypic 
pallidosubthalamic pathway and the arkypallidal/Npas1+ pallidostriatal pathway may 
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serve to have opposing roles in various behaviors similar to the STR. All prototypic 
neurons innervate at least one of the “downstream” BG nuclei, primarily the STN. 
Arkypallidal neurons only innervate the STR.  
As individual GPe neurons display heterogeneity in the firing frequency and 
regularity of their autonomous firing, long duration recordings have provided evidence 
that individual neurons, regardless of identity, can fluctuate or “wander” their firing 
frequency over a few minutes or spontaneously (Deister et al., 2013). In fact, the rate 
and pattern of individual neuron firing may sample all of the properties observed in the 
variable GPe population in totality. These findings emphasize the difficulty in 
discriminating prototypic and arkypallidal neurons by electrophysiological properties 
alone and that advances have been made by identifying molecular markers to 
discriminate prototypic from arkypallidal neurons (Deister et al., 2013). 
Very recently, it has been described that arkypallidal and prototypic neurons 
can be distinguished based on their activity across the sleep-wake cycle. This adds to 
the available techniques to distinguish between the two neuronal subtypes. 
 Specifically, arkypallidal neurons have a distinct function from prototytpic 
neurons as revealed by electrophysiological recording from “sleep-wake cycle 
identified” arkypallidal neurons in awake rats. In addition to supporting the evidence 
that the GPe contains two distinct cell types, these findings demonstrate that the GPe 
may play a role in arousal state.  
The Stop task utilizes a chamber in which a rat maintains its nose in a central 
port. In this task, a tone, or “Go” signal, instructs the rat to move its head to the left or 
right. A white noise burst serves as the “Stop” signal that signals the mouse to stop 
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the movement and fixate back in the central port. By screening neurons that changed 
firing rates shortly after the stop signal, evidence was provided that arkypallidal 
neurons provide a “Stop” signal by their GABAergic projections to the STR. The 
arkypallidal “Stop” signal cancels a “Go” signal which is sent by the STR to the SNr 
resulting in the ending of the imminent movement (Mallet et al., 2016). In addition to 
the cancellation of imminent movement, current theories of the indirect pathway 
(motor inhibiting) “Stop” function are that it serves to restrain unrewarded actions. 
As part of an integrated stress response, CRF is released. CRFR1 is expressed 
by very few Npas1 neurons, which are primarily arkypallidal and all send projections 
to the STR. If CRF is released in the GPe, I speculate that arkypallidal neurons would 
not “Stop” the stress response to promote survival. Prototypic neurons would send a 
“Go” signal, an action that promotes survival, in direct opposition of arkypallidal to STR 
stop signals, but this remains to be proven (Collins and Frank, 2014). 
In 6-OHDA lesioned rat models of Parkinson’s disease (PD), chronic dopamine 
depletion greatly decreases the firing of Npas1-STR neurons. PV+/prototypic neuron 
firing properties are not impacted by dopamine loss (Hernandez et al., 2015). As a 
result of dopamine loss, aberrant Npas1 neuron firing is likely caused by higher 
inhibitory tone. Inhibition from the STR becomes stronger in the absence of dopamine 
because the inhibitory D2 receptor is not activated. This would reduce the amount of 
GABA being released in the GPe allowing this indirect motor inhibiting pathway 
nucleus to fire more frequently. This suggests that input from the STR to the different 
neuronal subtypes of the GPe is not equal (Abdi et al., 2015). Of significance, I have 
shown that CRFR1 is expressed by prototypic neurons. The question is raised 
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whether a decrease in activity of Npas1 neurons in the dopamine depleted brain is 
further exacerbated by CRF signaling to CRFR1 prototypic neurons or if CRF signaling 
is modulated to counterbalance this abnormality.  
Determining the role of CRF/CRFR1 signaling in prototypic neurons becomes 
crucial if I want to provide evidence to whether or how CRF plays a role in Parkinson’s 
symptoms. With evidence that the two GPe neuronal subtypes receive differential 
inputs, their downstream targets must similarly be affected leading to aberrant 
functioning in other key basal ganglia nuclei that have the potential to be exacerbated 
by CRF/CRFR1 signaling.	
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CRF Neurons Project to and Make Synapses in the External Globus Pallidus
	 65	
In Brief  
	
 Previous experiments detecting CRF expression in the brain revealed that 
CRF+ fibers exist in the GPe of rat (Merchenthaler, 1984). The GPe expresses high 
levels of CRFR1; however, it is not considered a primary release site of CRF as only 
a single study has addressed the possible role of CRFR1 in anxiety-related behavior 
mediated by the GPe (Justice et al., 2008; Sztainberg et al., 2011; Van Pett et al., 
2000). The elusive question that remains is the source of CRF input to the GPe. 
 CRF neurons are highly concentrated in stress-responsive nuclei including the 
paraventricular nucleus of the hypothalamus (PVN), central nucleus of the amygdala 
(CeA) [(lateral (CeAl) and medial (CeAm)] and lateral dorsal subdivision of the bed 
nucleus of stria terminalis (BSTld) (Sawchenko et al., 1993). To determine if one 
nucleus preferentially projected to the GPe, I performed experiments to examine CRF 
neuronal projections to the GPe in mouse using immunohistochemistry in the triple 
transgenic mouse, CRFR1-GFP; CRF-cre; floxed-stop tdtomato (Ai9). These mice 
express GFP in neurons that express CRFR1 and the fluorescent reporter tdtomato in 
CRF neurons and fibers. To determine the origin of CRF input to the GPe, I utilized 
rabies virus mediated retrograde tracing in the novel BAC transgenic line CRFR1-cre 
which express Cre in neurons that express CRFR1 and found that CRF-rich stress 
regions make synapses on neurons that express CRFR1. As I observed a small 
population of Npas1+ neurons express CRFR1, I performed rabies tracing in Npas1-
cre mice as well. Npas1-cre mice express Cre in neurons that express Npas1 
(Hernández et al., 2015). Intriguingly, as Npas1 neurons that express CRFR1 are few 
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in number, I found that the same stress regions that project to CRFR1 expressing 
neurons project to Npas1 neurons as well. 
For the retrograde tracing experiments with rabies virus, I made bilateral 
stereotaxic injections of Cre-dependent TVA-mCherry/G encoding AAVs in the GPe 
of CRFR1-cre BAC and Npas1-cre BAC transgenic mice. Neurons successfully 
expressing the avian receptor TVA express mCherry in a distinguishable punctate 
fashion. The two gene cassettes, TVA and G, are required for the subsequent infection 
and transmission of the rabies virus (Fig.12 A). Two weeks later, I injected the same 
coordinates with pseudotyped rabies virus (PTRV) that expresses GFP (EnvA-
SADΔG-GFP). This modified rabies virus has had its coat protein, G, replaced with 
GFP (Fig.12 B). The virus is pseudotyped with the avian coat protein EnvA, which 
limits viral infection to neurons that express the avian receptor TVA. In the presence 
of G, also delivered in the first injection, the rabies virus can package and jump 
retrograde one synapse. Transmission is limited to one synapse because the newly 
infected neuron does not express G, and subsequently, the rabies virus cannot 
package and continue its retrograde “hop” (Wall et al., 2013; Watabe-Uchida et al., 
2012; Wickersham et al., 2007). This technique generally produced 5-10 “starter” 
neurons (neurons competent to generate rabies virus capable of retrograde 
transmission). “Starter” neurons are distinguished by their co-expression of TVA-
mCherry fluorescence and PTRV-GFP (Fig.12 C). Neurons that only express GFP are 
“traced” neurons which project to and make monosynaptic connections with “starter” 
neurons which are only located in the GPe as controlled by highly precise stereotaxic 
injection. Using this array of highly technical genetic tools and transgenic mice, I have 
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been the first to identify and map the source of synaptic input from CRF neurons to 
the GPe. 
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Results 
	
To investigate CRF neuron projections to the GPe, I imaged sections of the 
GPe from CRFR1-GFP; CRF-cre; floxed-stop tdtomato (Ai9) mice. CRF-IRES-Cre 
mice have been shown to express Cre accurately in neurons that express CRF (Chen 
et al., 2015; Taniguchi et al., 2011). In sections of the GPe, in mice carrying all three 
transgenes, CRFR1 neurons are green fluorescent and projections from CRF neurons 
are red fluorescent. tdtomato fibers from CRF neurons can be seen projecting within 
the GPe. The origin of these CRF neuron fibers remains unknown. Co-labeling for the 
presynaptic marker Synapsin-1 reveals presynaptic terminals between tdtomato+ 
axonal fibers and CRFR1-GFP+ dendrites and cell bodies (Fig.11 A-D), identified 
visually. 
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Figure 11. CRF neurons have presynaptic terminals and CRF peptide located in 
the GPe. Images of the GPe from mice carrying CRFR1-GFP, CRF-cre and a Cre 
dependent tdtomato reporter (lsl- tdtom) reveal projections from CRF neurons in close 
proximity to CRFR1-GFP+ neurons. (A-D) Staining of sections for Synapsin-1 
identifies synaptic puncta where the projections meet (arrows), as well as puncta that 
are Synapsin-1 negative (arrowheads). (E-H) Staining for CRF peptide shows that 
many of the larger puncta contain CRF peptide in the GPe. Scale bar = 25 µm 
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When I stained for CRF peptide, CRF is located in tdtomato+ axonal puncta in 
the GPe, adjacent to CRFR1-GFP+ dendritic fibers (Fig.11 E-H). The evidence 
provided by these experiments indicates that presynaptic terminals of CRF neurons 
exist in the GPe which possibly release CRF onto cell bodies and dendrites of CRFR1-
GFP+ neurons. These experiments did not definitively confirm that CRF is released at 
these terminals. In addition, staining for Synapsin-1 in the absence of co-staining with 
a postsynaptic marker does not allow for the conclusion that synapses between CRF 
neuron fibers and CRFR1-GFP neurons are present. These experiments demonstrate 
that (1) CRF neurons project to the GPe, (2) CRF is present in CRF neuronal fibers in 
the GPe, and (3) CRF fibers have presynaptic terminals in close proximity to CRFR1 
expressing neurons.  
To provide evidence that CRF neurons make synapses on CRFR1 neurons, I 
utilized the PTRV technique to reveal the synapse formation between CRFR1 “starter” 
neurons and CRF-positive “traced” neurons. To identify CRF neurons, I made ICV 
injections of colchicine to stop vesicular transport into mice that had undergone the 
PTRV procedure to allow for staining of CRF neurons. As CRF is a neuropeptide, it is 
located in vesicles throughout the axon. When staining for CRF followed by a 
secondary fluorophore, the resulting fluorescence will appear in fields instead of single 
neurons. By stopping vesicular transport, CRF vesicles remain in the soma. This 
allows immunohistochemistry to identify individual neurons that contain the 
neuropeptide (Wang et al., 2011).   
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Using CRFR1-cre mice, this is the first study to provide evidence not only from 
where CRF input to the GPe originates but that it originates in key stress nuclei; the 
BSTld (Fig.12 D-F), PVN (Fig.12 G-I), and CeAl (Fig.12 J-L). When I stained for CRF 
in Npas1-cre mice, I found that the same nuclei; the BSTld (Fig.13 A-C), PVN (Fig.13 
D-F), and CeAl (Fig.13 G-I), project to Npas1 neurons.  The CRF neurons most likely 
project to the small proportion of Npas1 neurons that express CRFR1. I calculated a 
connectivity ratio of the observed neurons in the stress regions. The connectivity ratio 
is defined as the number of “traced” neurons in each nucleus per “starter” neurons in 
the GPe. I found that the stress region connectivity ratio in CRFR1-cre and Npas1-cre 
is distinct indicating differential patterns of innervation. Npas1 neurons have a 
significantly higher connectivity ratio from both the CeAl (2.23 ± 0.33 vs. 0.97 ± 0.27; 
t(9)=2.87, p<0.05)  and CeAm (0.88 ± 0.34 vs. 0.08 ± 0.04; t(6)=3.18, p<0.01) compared 
to the stress region connectivity ratio in CRFR1-cre mice. Tracing in CRFR1-cre mice 
revealed that the PVN has a higher connectivity ratio (0.47 ± 0.26 vs. 0.14 ± 0.08; 
t(8)=1.22, p=0.25) compared to Npas1-cre, although this did not reach statistical 
significance likely due to variability in injections. The connectivity ratio from the BSTld 
did not differ (Fig.14 A). It is intriguing that CRFR1+ neurons and Npas1+ neurons 
receive differential input from the stress regions. This suggests that possibly the stress 
regions activate the neurons at different times or that they may have disparate 
functions. For example, the activation of CRFR1+ neurons by the PVN may occur 
during the activation of the stress response as CRF neurons release CRF at the 
initiation of the stress response. It is possible that the CeA may preferentially target 
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Npas1+ neurons at the termination of the stress response but this remains to be 
explored.   
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Figure 12. Rabies viral tracing of monosynaptic inputs to GPe CRFR1+ neurons. 
(A) Injection of AAV helper viruses encoding Cre-dependent TVA-mCherry (red) and 
G allow for infection by EnvA pseudotyped, G-deleted rabies virus that expresses GFP 
(B, SADΔG-GFP, green). (C) The merged image shows a “starter” neuron that 
expresses both the helper and the rabies viruses (yellow, arrow) surrounded by 
neurons expressing GFP only (green, arrowheads) which make synapses on a 
“starter” neuron. In mice traced from CRFR1+ neurons in the GPe, I found connected 
neurons in the BSTld (D-F), the PVN (G-I) and the CeAl (J-L). Staining of sections of 
these nuclei show that some of these neurons contain CRF peptide (magenta, 
arrows), while other neurons do not (arrowheads). A-C; D-L = 50 µM. 
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Figure 13. CRF neurons project to Npas1+ GPe neurons. CRF staining of sections 
from Npas1-cre tracing experiments. I found CRF neurons (magenta) in the BSTld (A-
C), PVN (D-F), and CeA (G-I) that were traced from Npas1+ neurons in the GPe 
(green). Arrows indicate “traced” neurons that are positive for CRF peptide, 
arrowheads indicate “traced” neurons that are CRF negative. Scale bar = 50 µm. CeAl 
= lateral division of the central nucleus of the amygdala. CeAm = medial division of 
the central nucleus of the amygdala.  
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Figure 14. Quantification of the connectivity between key stress responsive 
nuclei and CRFR1 neurons (red) and Npas1 neurons (blue) in the GPe. (A) The 
CeAl and CeAm make more connections with Npas1+ neurons than with CRFR1+ 
neurons. * = p<0.05; ** = p<0.01, n=3 per transgenic mouse line. Connectivity ratio is 
the number of “traced” neurons present in each nucleus per “starter” neuron in the 
GPe. 	
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Conclusions 
 
These experiments provide evidence of the origin of CRF input to the GPe, 
which was previously unknown. I provide novel evidence that the source of this input 
is from key stress regions of the brain. Tracing experiments in CRFR1-cre mice 
indicate that the BSTld, CeA, and PVN send projections and synapse onto CRFR1 
neurons in the GPe. While this has never been shown before, it was not completely 
unexpected because these regions express CRF abundantly. What was unexpected 
is that the same regions project to Npas1 neurons in the GPe. Presumably, it is the 
small population (<7%) of CRFR1 neurons that express Npas1 that receive 
projections from CRF neurons in stress regions. The question is raised as to why the 
Npas1+/CRFR1+ neurons receive projections from the same regions that project to 
exclusively CRFR1 expressing neurons. Performing the tracing study in both CRFR1-
cre and Npas1-cre lines raises the possibility that all prototypic neurons receive CRF 
synapses from stress regions. Interestingly, as discussed previously, prototypic 
neurons form the pallidosubthalamic tract while Npas1 neurons project exclusively to 
the STR. This implies that there may be different functions of CRF in the GPe. A small 
minority of CRFR1 expressing Npas1 neurons projecting to the STR may allow CRF 
to bias striatal functioning and output. The primary input to the GPe is the STR. CRFR1 
receptors on Npas1 neurons would allow for CRF/CRFR1 signaling to provide 
feedback from GPe activity to the STR. The GPe is a GABAergic nucleus and sends 
inhibitory signals primarily to the STN (DeLong and Wichmann, 2007). As part of the 
GPe, Npas1 neurons are also GABAergic and transmit inhibitory tone to the STR. This 
CRF-activated pallidostriatal pathway may create an inhibition of inhibition loop. 
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Depending on the MSNs that Npas1 neurons project to, which is yet to be determined, 
CRF activation of Npas1+/CRFR1+ neurons may increase activity in the GPe by 
inhibiting the inhibition feeding into the GPe from the STR. In addition, CRF activation 
of the canonical prototypic neurons may act synergistically to allow CRF/CRFR1 
signaling to activate the GPe while simultaneously decreasing inhibitory input from the 
STR.  
The only glutamatergic, excitatory nucleus in the BG is the STN projection to 
the GPi (DeLong and Wichmann, 2007). Based on recent literature that proposes the 
GPe projects to all nuclei in the BG, it becomes apparent that an additional source of 
excitatory neuron activating neuropeptide such as CRF could have a dramatic effect 
on the function of many regions in the BG. Another point of interest is that tracing done 
in CRFR1-cre mice indicates that there are more projections from the PVN to the 
CRFR1 GPe population while there are more projections from the CeAl and CeAm 
nuclei to GPe Npas1 neurons. PVN CRF neurons are able to co-release excitatory 
glutamate, while CeA CRF neurons co-release inhibitory GABA (Füzesi et al., 2016; 
Partridge et al., 2016). PVN CRF neurons may communicate with CRFR1 expressing 
GPe neurons first through fast glutamatergic synapses to activate neurons followed 
by CRF to maintain their activation at the initiation of a stress response. The CeA may 
dampen the effects of CRF on Npas1 neurons by co-release of GABA restoring 
inhibition from the STR possibly at the termination of a stress response.  
In summary, this study is the first to provide evidence that CRF neurons in key 
limbic and autonomic stress regions through long-range projections form synaptic 
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connections with GPe neurons indicating that the GPe and basal ganglia may play an 
important role in the stress response not yet characterized. 
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Interconnectivity of Prototypic and Arkypallidal Neurons in the GPe 
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In Brief 
 
In the last chapter, I utilized PTRV tracing techniques to identify novel long-
range CRF projections between key stress regions and CRFR1+ or Npas1+ neurons 
in the GPe. While quantifying the number of “traced” neurons in sections from the 
entire brain, I uncovered that the GPe contains complex microcircuitry. To evaluate 
local GPe connectivity, I utilized PTRV retrograde tracing in both CRFR1-cre and 
Npas1-cre mice and immunohistochemistry with specific markers to neuronal 
subtypes in the GPe. In the interconnected GPe, I found that CRFR1+ prototypic 
neurons only receive synaptic input from other prototypic neurons. This finding may 
be extrapolated to propose the hypothesis that only prototypic neurons synapse on 
other prototypic neurons within the GPe.   
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Results 
	
 As part of my analysis of PTRV mice, I calculated a connectivity ratio for the 
major regions projecting to the GPe. Once I completed the necessary injections for 
the PTRV technique and sacrificed the mice, I prepared brain sections from the entire 
brain. I visually inspected the sections for neurons expressing GFP, “traced” neurons. 
I quantified the number of “traced” neurons in numerous brain regions known to send 
projections to the GPe or BG. Also, I included the hypothalamus and amygdala due 
to their close proximity to the GPe. Once I quantified the number of “traced” neurons 
throughout the brain, I quantified the number of “starter” neurons in the GPe and 
calculated a connectivity ratio for each region the same way I calculated the 
connectivity ratio for stress regions. The STR is known to be the primary source of 
input to the GPe, however I found that the nucleus with the second highest input to 
the GPe was the GPe itself, manifesting almost the same connectivity ratio as that of 
the STR. For example, the ratio between “traced” striatal neurons to “starter” GPe 
neurons is ~12 to 1.  Likewise, the ratio between “traced” CRFR1+ GPe neurons to 
“starter” GPe CRFR1+ neurons is ~10 to 1 (Fig.15 A). This provides support for an 
argument that the GPe is highly interconnected and forms an inhibitory network as the 
GPe is GABAergic.  
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Figure 15. Quantification of CRFR1-cre (red) and Npas1-cre (blue) monosynaptic 
tracing experiments expressed as a Connectivity Ratio. (A) Connectivity ratio is 
the number of traced neurons in each region divided by the number of starter neurons 
in that experiment. n=3 mice per line. Str = Striatum, GPe = external globus pallidus, 
STn = Subthalamic Nucleus, Amyg = Amygdala, Thal = Thalamus, Hypo = 
Hypothalamus, SNc = Substantia Nigra pars compacta. 
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In CRFR1-cre mice, I observed “starter” neurons that were positive for the 
prototypic markers Nkx2.1 (Fig.16 A) and PV (Fig.16 B). Also, I observed “starter” 
neurons that were positive for Npas1 (Fig.16 C), suggesting that these neurons 
represent the small population of CRFR1+/Npas1+ prototypic neurons. I did not 
observe any CRFR1+ “starter” neurons that were positive for the arkypallidal marker 
FoxP2 (Fig.16 D). These results are consistent with my findings from the experiments 
using the CRFR1-GFP mice as described previously.  
In Npas1-cre mice, I observed “starter” neurons that were positive for either 
Nkx2.1 (Fig.17 A), Npas1 (Fig.17 C), or FoxP2 (Fig.17 D). I did not observe any 
“starter” neurons that were positive for PV as Npas1 and PV neurons are a non-
overlapping class (Fig.17 C) (Hernández et al., 2015). While some Npas1-cre mice 
had “starter” neurons that were positive for Nkx2.1, suggesting that these are 
prototypic neurons; overwhelmingly, Npas1-cre “starter” neurons co-express the 
arkypallidal marker FoxP2. These results indicate that “starter” neurons generated in 
CRFR1-cre are prototypic while “starter” neurons generated in Npas1-cre are 
pallidostriatal projecting, as they are Npas1+. Additionally, the majority have a high 
probability of having arkypallidal neuronal identity (FoxP2). In the case of Npas1, 
combining the visibility of Cre through mCherry expression and neuron specific 
markers, I was able to be confident that Npas1-cre expresses Cre in the pattern I 
expect based on previous findings from other groups. Other groups have likewise 
demonstrated that co-expression of Npas1 with Nkx2.1 or FoxP2 exists (Abdi et al., 
2015; Dodson et al., 2015; Hernández et al., 2015). This confirms that any future 
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experiments using these Cre lines are reliable because Cre is expressed in the correct 
neurons.  
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Figure 16. Characterization of “starter” neurons in CRFR1-cre rabies viral 
tracing experiments. Staining for markers of GPe subtypes reveals “starter” neurons 
positive for Nkx2.1 (A), PV (B), Npas1 (C), but not FoxP2 (D). Large arrow indicates 
a “starter” neuron, small arrow indicates a TVA-mCherry expressing neuron that is not 
infected with rabies virus but expressing molecular marker, Scale bar = 25 µm. 
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Figure 17. Characterization of “starter” neurons in Npas1-cre rabies viral tracing 
experiments. Staining for markers of GPe subtypes reveals “starter” neurons positive 
for Nkx2.1 (A), Npas1 (C), and FoxP2 (D). No “starter” neurons were positive for PV 
(B). Large arrow indicates a “starter” neuron, small arrow indicates a TVA-mCherry 
expressing neuron that is not infected with rabies virus but expressing molecular 
marker. Scale bar = 50 µm.  
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Next, I examined the “traced” neurons in CRFR1-cre mice. I observed that 
Nkx2.1 (Fig.18 A), PV (Fig.18 B), and Npas1 (Fig.18 C) neurons project to and make 
synapses on CRFR1 expressing neurons. Noticeably, FoxP2 arkypallidal neurons do 
not send projections to CRFR1 expressing neurons (Fig.18 D). When I examined 
“traced” neurons in Npas1-cre mice, I found that Nkx2.1 (Fig.19 A), PV (Fig.19 B), 
Npas1 (Fig.19 C), and FoxP2 (Fig.19 D) neurons send projections to and make 
synapses onto Npas1 neurons. 
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Figure 18. Characterization of “traced” neurons in CRFR1-cre rabies viral 
tracing experiments. Staining of traced neurons present in the GPe in CRFR1-cre 
experiments revealed Nkx2.1+ (A), PV+ (B), and Npas1+ (C) “traced” neurons, but 
not FoxP2+ “traced” neurons (D). Arrows indicate double positive neurons.  
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Figure 19. Characterization of “traced” neurons in Npas1-cre rabies viral tracing 
experiments. Staining of traced neurons present in the GPe in Npas1-cre 
experiments revealed Nkx2.1+ (A), PV+ (B), and Npas1+ (C) “traced” neurons, as well 
as FoxP2+ “traced” neurons (D). Arrows indicate double positive neurons. Scale bar 
= 25 µm for both Fig.18 and Fig.19. 
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Conclusions    
	
I studied the connectivity of prototypic and arkypallidal neurons of the GPe 
using PTRV that was specifically expressed in either neuronal cell type. Using rabies 
mediated viral retrograde tracing, I provide evidence that the second largest source of 
input to the GPe is the GPe itself.  
As the CRFR1-cre line is a novel BAC transgenic in which mCherry expression 
is a surrogate for Cre expression, it is important to validate that mCherry co-expresses 
with known markers of CRFR1+ neurons. My evidence shows that Cre expression in 
the CRFR1-cre transgenic mouse mimics the GFP expression in the CRFR1-GFP 
transgenic mouse. Specifically, Cre co-expresses with CRFR1+ neuronal markers 
Nkx2.1, PV, and Npas1. Together, these results demonstrate that CRFR1 expression 
is restricted to prototypic GPe neurons. In contrast, “starter” neurons in Npas1-cre 
transgenic mice co-expressed Nkx2.1, Npas1, and FoxP2, but not PV, which is 
consistent with published reports. In fact, Npas1 and PV have been shown to be 
distinct non-overlapping classes (Abdi et al., 2015; Dodson et al., 2015; Hernández et 
al., 2015).  
Regarding the connectivity between prototypic and arkypallidal neurons, I 
demonstrate that CRFR1 expressing prototypic neurons receive projections from 
prototypic neurons but not arkypallidal neurons. As not all prototypic neurons express 
CRFR1, it is possible that some prototypic neurons receive projections from FoxP2+ 
arkypallidal neurons. Although I did not observe any FoxP2+ “traced” neurons that 
project to CRFR1+ neurons during my extensive visual analysis, it is possible that 
because CRFR1 is expressed in much greater abundance than FoxP2, I did not 
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observe any CRFR1+/FoxP2+ neurons that may have been present in my GPe brain 
sections.  
On the other hand, projections from Npas1-cre neurons did not demonstrate 
selectivity. Specifically, I found that Nkx2.1, PV, Npas1, and FoxP2 neurons project to 
and make synapses on Npas1 neurons. Previously, I demonstrated that Npas1 
neurons can express prototypic or arkypallidal markers.  Based on my findings that 
both subtypes synapse on Npas1 neurons, I hypothesize that these neurons serve to 
integrate prototypic and arkypallidal processing.  For example, a arkypallidal neuron 
could provide feedback to the STN by synapsing on CRFR1+ prototypic neurons.  I 
also believe that there are likely many uncharacterized neuronal subtypes that 
contribute to the inter-nuclear circuits of the GPe. 
The connectivity within the GPe is likely much more complex than the current 
state of the field.  Future research should include paired electrophysiological 
recordings between synaptically linked prototypic and/or arkypallidal neurons and the 
generation of a FoxP2-cre transgenic mouse line.  This mouse line could be used to 
examine whether FoxP2+ arkypallidal neurons synapse on Npas1+ prototypic 
neurons.  
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Activation of CRFR1+ Neurons and Npas1+ Neurons has Contrasting Effects 
on Anxiety-related behavior and Movement 
	 97	
In Brief 
	
 Over the course of this study, I have determined that CRFR1 expressing 
neurons are prototypic GPe neurons. I provided evidence to the novel finding of where 
CRF input to the GPe originates. I revealed that CRFR1+ and Npas1+ neurons in the 
GPe receive monosynaptic projections from CRF neurons in the key stress nuclei: the 
BSTld, CeA, and PVN. Also, I have provided evidence that there is a complex 
microcircuit within the GPe neuronal subtypes. What remains unanswered is the 
functional relevance of activation of CRFR1 expressing neurons, which primarily 
comprise the pallidosubthalamic pathway, and the Npas1 pallidostriatal projections on 
behavior. Specifically, how do these two GPe neuronal subtypes modulate anxiety-
related behavior?  
 To decipher the functional role of these neuronal subtypes, I took advantage of 
Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology. 
This technology allows for the expression of Gq-coupled protein receptors in neurons 
that exclusively express Cre. These receptors are activated by an inert drug, clozapine 
N-oxide (CNO). This scheme provides robust activation of neurons expressing Gq-
coupled DREADDs. When bound by CNO, Gq DREADDs activate the phospholipase 
C (PLC) pathway that ultimately results in the release of Ca2+ from the endoplasmic 
reticulum (ER) increasing cytosolic calcium levels leading to activation of neurons. 
Using the BAC transgenic CRFR1-cre line, I performed experiments to determine the 
effect on behavior when activating the prototypic population. Using the BAC 
transgenic Npas1-cre line, I evaluated the functional consequence on behavior of 
activation of the Npas1+ pallidostriatal/arkypallidal pathway. As I am examining the 
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stress peptide CRF and its receptor CRFR1, which is responsible for the anxiogenic 
effect of CRF, I decided to assay my mice in a variety of behavioral paradigms that 
test for anxiety-related behavior as well as movement. I infected CRFR1-cre and 
Npas1-cre mice with Cre-dependent DREADD-Gq virus (AAV-EF1a-DIO-hM3Dq-
mCherry) in the GPe (Armbruster et al., 2007). This allowed for the expression of Gq 
DREADDs in either CRFR1 neurons or Npas1 neurons depending on the mouse 
strain. 
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Results 
	
In CRFR1-cre mice, the viral infection led to GPe-specific expression of 
hM3Dq-mCherry in Nkx2.1+ and PV+ prototypic neurons (Fig.20 A, B). In Npas1-cre, 
the majority of GPe neurons expressing DREADD-Gq were Npas1+/FoxP2+ (Fig.20 
C, D). 
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Figure 20. Confirmation of neuronal DREADD Expression. 
In CRFR1::GPe-Gq mice, I verified that prototypic neurons were expressing 
DREADDs using markers Nkx2.1 (A) and PV (B). In Npas1::GPe-Gq mice, I verified 
expression by Npas1+ neurons (C) and arkypallidal neurons labeled by FoxP2 (D). 
Scale bar = 25 µm 
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After confirming the expression of prototypic neurons in CRFR1::GPe-Gq mice 
and Npas1+/FoxP2+ arkypallidal neurons in Npas1::GPe-Gq mice, I collected data 
from a battery of behavioral paradigms testing for anxiety-related behavior and in 
some cases movement as well. Before performing any behavioral test, I allowed the 
mice to acclimate to the testing room and then administered an intraperitoneal (IP) 
injection of CNO. I waited fifteen minutes for the CNO to robustly activate the 
DREADD-Gq expressing GPe neurons before the commencement of testing. 
I first tested the mice in the Light Dark Transfer Assay (LDT). This test consists 
of an enclosed arena with a light side and a dark side separated by a hole large 
enough for the mouse to easily pass. The LDT measures anxiety-related behavior by 
the mouse’s level of aversion to the light side of the maze. Specifically, the LDT 
measures passive avoidance of stressful situations. As mice are nocturnal, they prefer 
the dark side of the arena versus the light side. The more times a mouse transfers 
from the dark side to the light side of the maze, a decrease in anxiety-related behavior 
is inferred (Cryan and Holmes, 2005).  
I found an opposing effect on anxiety-related behavior when CRFR1::GPe-Gq 
neurons or Npas1::GPe-Gq neurons were activated. In CRFR1::GPe-Gq mice, I 
observed a significant decrease in the number of light entries compared to CRFR1-
cre control virus injected mice (Cre-dependent mCherry) (10.83 ± 1.48 vs. 19.11 ± 
2.29 .88, t(19)=2.81, p<0.05), suggesting activation of CRFR1+ GPe neurons elevates 
anxiety-related behavior (Fig.21). Of note, I also tested CRFR1::GPe-Gq and 
Npas1::GPe-Gq mice injected with saline and found no difference between control 
virus mice injected with CNO and DREADD-Gq mice  
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Figure 21. Activation of CRFR1 and Npas1 neurons has opposing effects on 
anxiety-related behavior on the LDT. (A) On the LDT, I saw a decrease in light 
entries in CRFR1::GPe-Gq mice (dark red) and an increase in Npas1::GPe-Gq mice 
(dark green), indicating an opposing effect of activation of CRFR1 or Npas1 GPe 
neurons on anxiety-related behavior. (B) I observed no difference between 
experimental and control animals in total distance traveled for either transgenic mouse 
line. CRFR1-cre: CRFR1::GPe-Gq n=9, n=12 control. Npas1-cre: Npas1::GPe-Gq 
n=9, n=9 control. 
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injected with saline, therefore the controls were combined for all experiments. In 
contrast, I observed a significant increase in the number of light entries in 
Npas1::GPe-Gq mice compared to control Npas1-cre control virus injected mice 
(12.11 ± 1.87 vs. 5.44 ± 0.87, t(16)=3.24, p<0.01), indicating that Npas1+ neuron 
activation decreases anxiety-related behavior (Fig.21 A). In both CRFR1::GPe-Gq 
mice and Npas1::GPe-Gq mice, I did not observe a difference in total distance traveled 
on the LDT (Fig.21 B). 
 To assess active expressions of anxiety-related behavior, I used the marble 
burying task in which anxiety is measured as a function of the number of marbles 
buried in bedding. The more marbles buried, it is inferred that the mouse is displaying 
greater anxiety-related behavior (Kedia and Chattarji, 2014). With activation of 
CRFR1::GPe-Gq neurons, the number of marbles buried was significantly increased 
compared to control infected mice (82.50 ± 6.02 % vs. 38.57 ± 4.04 %, t(15)=5.50, 
p<0.001) (Fig.22 A). With activation of Npas1::GPe-Gq neurons, the number of 
marbles buried was significantly decreased compared to corresponding Npas1-cre 
control mice (40.00 ± 4.08 % vs. 76.00 ± 8.12 %, t(7)=3.64, p<0.01) (Fig.22 A).  
 In both the LDT and marble burying task, I consistently observed a baseline 
anxiety phenotype in Npas1-cre mice making direct comparisons between the two Cre 
lines not possible. It is possible that the difference in baseline anxiety is a result of the 
location of the gene insertion when the BAC transgene was generated. Also, it is 
plausible that Cre expression in neurons may alter their baseline function. By 
backcrossing Npas1-cre mice to C57BL/6 mice, I may be able to assess if the resulting 
phenotype is an artifact of a mixed background created from generations of  
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Figure 22. CRFR1 and Npas1 neuron activation have opposing effects on marble 
burying. (A) Activation of CRFR1::GPe-Gq neurons resulted in significantly more 
marbles buried than CRFR1-cre controls, while Npas1::GPe-Gq mice buried 
significantly less marbles than their corresponding Npas1-cre controls. Note the 
difference between the two unmanipulated Cre lines. CRFR1-cre: CRFR1::GPe-Gq 
n=7, n=10 control. Npas1-cre: Npas1::GPe-Gq n=5, n=4 control. 
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breeding. However, both tests support the conclusion that activating CRFR1+ GPe 
neurons elevates anxiety-related behavior while activating Npas1+ GPe neurons 
decreases anxiety-related behavior.  
 While I did not see changes in the total distance traveled on the LDT between 
control and CNO-treated mice (Fig.21 B), I consistently observed more movement in 
CRFR1::GPE-Gq mice and less movement in Npas1::GPe-Gq mice. To further 
explore how activation of these neuronal populations impact activity, I measured 
movement in the relatively low anxiety eliciting context of the open field assay (OFA) 
(Bale et al., 2000). The open field consists of an empty arena with plexi glass siding. 
The mouse can stay close within the walls of the maze (protected due to thigmotaxis), 
which represents a greater level of anxiety-related behavior, or venture into the open 
center region (unprotected) representing decreased anxiety-related behavior.  
 With activation of CRFR1 neurons, I observed a significant increase in the total 
distance traveled in CRFR1::GPe-Gq mice (4498.94 ± 236.00 cm vs. 3602.70 ± 
265.36 cm, t(25)=2.43, p<0.05) (Fig.23 A). Conversely, with activation of Npas1+ 
neurons, I observed a significant decrease in total distance traveled in Npas1::GPe-
Gq mice (2675.00 ± 322.66 cm vs. 3652.60 ± 69.85 cm, t(18)=2.96, p<0.01) (Fig.23 A). 
However, comparing CRFR1::GPe-Gq mice to Npas1::GPe-Gq mice, movement was 
biased toward protected or exposed regions of the open field, suggesting a strong 
anxiety component to the movement.  Specifically, in CRFR1::GPe-Gq mice, I 
observed elevated levels of movement in the surround regions (protected) of the open 
field (4065.41 ± 229.49 cm vs. 3012.00 ± 351.90 cm, t(25)=2.62, p<0.05) (Fig.23 B) and 
a lower center/total time ratio (12.7 ± 1.2 % vs. 21.4 ± 4.9 %, t(25)=2.154, p<0.05) 
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(Fig.23 C). The higher the center/total time ratio, it is interpreted to represent 
decreased anxiety-related behavior (Bale et al., 2000). In Npas1::GPe-Gq mice, I saw 
the opposite effect; mice moved less in the surround region of the maze (2323.60 ± 
304.45 cm vs. 3489.50 ± 2.29 cm, t(18)=3.51, p<0.01) (Fig.23 B) and displayed a higher 
center/total time ratio (11.5  ± 1.9 % vs. 6.6 ± 0.6 %, t(18)=2.39, p<0.05) (Fig.23 C). 	
In summary, activation of CRFR1 neurons in the GPe biases the mice toward 
increased movement in protected regions of the maze, while activation of Npas1 GPe 
neurons causes animals to decrease their movement and bias towards open, less 
protected areas of the maze (Fig.24 A). These data demonstrate that activation of 
CRFR1 neurons increases anxiety-related behavior and movement while Npas1 
neuronal activation leads to a decrease in anxiety-related behavior and movement.  
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Figure 23. CRFR1 and Npas1 neuron activation has opposing effects on anxiety-
related behavior in the open field assay. (A) CRFR1::GPe-Gq animals displayed 
more total movement in the open field than controls, while Npas1::GPe-Gq animals 
displayed less movement than controls. (B) This movement was biased toward 
particular regions of the maze, as CRFR1::GPe-Gq animals moved more in the 
surround regions of the maze and Npas1::GPe-Gq mice moved less in the surround. 
(C) This difference resulted in a decrease in the center time ratio in CRFR1::GPe-Gq 
mice and an increase in center time ratio in Npas1::GPe-Gq mice, indicating elevated 
and decreased anxiety-related behavior, respectively. CRFR1-cre: CRFR1::GPe-Gq 
n=10, n=17 controls, Npas1-cre: Npas1::GPe-Gq n=10, n=10 controls. 
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Figure 24. Heatmaps of time duration at locations on OFA. (A) Heatmaps of 
example open field assays display biasing of movement to opposite regions of the 
maze with activation of CRFR1 GPe neurons (top maps), and Npas1 GPe neurons 
(bottom maps). Less time is indicated by blue and more time is indicated by red. 
CRFR1::GPe-Gq mice spend less time in the center compared to controls suggesting 
an increase in anxiety-related behavior. Npas1::GPe-Gq mice spend more time in the 
center compared to controls interpreted as a decrease in anxiety-related behavior. 
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Conclusions 
	
We tested CRFR1::GPe-Gq and Npas1::GPe-Gq mice on a battery of 
behavioral paradigms used to measure anxiety-related behavior and mobility including 
the LDT, OFA and marble burying task. If I had tested the mice in a purely motor task 
such as the DigiGait, which measures the speed and pace of movement, I may have 
never observed the anxiety phenotype (Berryman et al., 2009). All three task indicated 
that activation of CRFR1 neurons increases anxiety-related behavior and activation of 
Npas1 neurons decreases anxiety-related behavior. Specifically, in the LDT assay, 
mice with activated CRFR1 neurons explore the illuminated section less than mice 
with activated Npas1 neurons. While the LDT assay measures passive anxiety 
(baseline anxiety), the marble burying task is an indicator of active anxiety because 
the animal actively relieves themselves of the stress producing, noxious agent i.e. by 
burying the marbles.  In the marble burying task, I observed that activation of CRFR1 
neurons significantly increases active anxiety-related behavior, while Npas1 neuron 
activation reduces active anxiety-related behavior. Finally, the OFA was very 
informative about the animal’s anxiety level. CRFR1 neuron activation leads to a 
hypermobile, increased anxiety-related behavior state. Specifically, the hypermobility 
occurred in the more protected region of the maze. In contrast, Npas1::GPe-Gq 
animals move less in the surround protected region of the maze and venture into the 
open field more often indicating lower anxiety-related behavior.  
I did not observe a difference in total distance traveled in CRFR1::GPe-Gq and 
Npas1::GPe-Gq mice on the LDT, while I did observe this phenomenon on the OFA. 
A possible reason for this result is that the LDT is not a test of general mobility. Its 
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primary use is to determine a mouse’s relative anxiety-related behavior by the number 
of transitions into the light. The interpretation that the mice are more anxious is based 
on their lack of transitions into the light region; Additionally, the way the LDT is 
recorded and scored may obscure the movement component of the anxiety-related 
behavior.  
On the OFA, there is no region for the mice to “hide” such as on the LDT. The 
increase in distance traveled while the mice are displaying thigmotaxic behavior in the 
case of CRFR1::GPe-Gq compared to control mice may represent an active 
avoidance of the center anxiety eliciting region. The interpretation that CRFR1::GPe-
Gq mice are displaying an increase in movement in the OFA as a component of 
anxiety is strengthened by my results on the marble burying task, which is a measure 
of active anxiety. It is likely that I would have observed increased movement in the 
CRFR1::GPe-Gq mice as more movement is required to bury more marbles. 
I interpreted the increased movement in the OFA surround region by the 
CRFR1::GPe-Gq mice as increased anxiety-related behavior based on contrasting 
behavior manifested due to activation of CRFR1 or Npas1 neurons. Specifically, 
anxiety manifests as increased movement on the OFA in CRFR1::GPe-Gq mice and 
the decreased movement in Npas1::GPe-Gq mice. More behavioral paradigms such 
as the elevated-plus maze (EPM), which measures anxiety-related behavior by the 
mice’s time in an open, exposed region of the maze elevated off the floor, may help 
resolve this issue. Due to experimental limitations, I was unable to perform this 
paradigm. 
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The PVN is not known to play a direct role in the behavioral outcomes of the 
initiation of the stress response. The PVN is the activator of the endocrine (HPA-
axis) and autonomic cascade that is the stress response. The possibility that it plays 
a direct role in the experience of anxiety is novel (Dabrowska et al. 2011). Interestingly, 
the PVN may release fast acting excitatory glutamate with CRF at the initiation of the 
stress response to increase both anxiety-related behavior and movement. As I have 
demonstrated, CRF neurons in the PVN preferentially target CRFR1+ prototypic 
neurons while CeA CRF neurons preferentially target Npas1+/arkypallidal neurons 
(Fig.14 A). Intriguingly, overexpression of CRF in the CeA leads to a reduction in 
stress-induced anxiety (Kormos and Gaszner 2013). The CeA may release CRF into 
the GPe to activate the “Stop” function of the arkypallidal pathway when a stress 
response is no longer beneficial or the stressor is insufficiently noxious (Mallet et al., 
2016). While the activation of the stress response promotes survival, the modification 
of bodily functions induced by the stress response are only beneficial for a limited 
period of time. As CRFR2 (which may oppose the actions of CRFR1) is not expressed 
in the GPe, the only way to terminate the GPe-mediated stress response may be 
through classic BG function of inhibiting unwanted actions (Kormos and Gaszner, 
2013). Activation of the Npas1+/arkypallidal pathway may serve to stop the stress 
response. 
 As I used Gq DREADDs to activate CRFR1 or Npas1 neurons, further study is 
needed to provide evidence that it is in fact CRF that is released from the PVN or the 
CeA into the GPe that mediates the anxiogenic or anxiolytic effects. One means of 
addressing this question is to artificially stimulate CRF neurons in either the PVN or 
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CeA using Cre-dependent Channelrhodopsin (ChR2). ChR2 is a non-specific cation 
channel that opens in response to blue light delivered by a fiber optic implant (Boyden 
et al., 2005). To perform this experiment, ChR2 would be expressed in CRF PVN 
neurons in CRF-cre mice introduced by bilateral stereotaxic injection. The fiber optic 
would be placed in the GPe and upon blue light stimulation, I anticipate CRF will be 
released and I would assess for anxiety-related behavior. To ensure that it is actually 
CRF and not a fast acting neurotransmitter mediating the behavior, a CRFR1 specific 
antagonist such as R121919 would be administered to the mouse for several days to 
allow the antagonist to reach steady state prior to testing (Gutman, 2003). Similar 
experiments could be performed with ChR2 in CRF neurons in the CeA. These 
experiments will allow a more detailed assessment of functional consequences of 
activation of distinct CRF neuronal subtypes. While DREADDs have a long lasting 
effect on neuronal activity, ChR2 has control of neuronal activation at the millisecond 
time scale (Armbruster et al., 2007; Boyden et al., 2005).  Using both techniques 
together would strengthen any conclusion drawn by a single technique. 
In closing, I have provided evidence of a novel function of the GPe in its ability 
to confer bidirectional control over anxiety-related behavior through CRFR1 and 
Npas1 neurons.
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Experimental Conclusions 
	
Throughout the course of this study, I have made many novel discoveries. First, 
I performed electrophysiological experiments to verify that only GFP fluorescent 
neurons in the CRFR1-GFP mouse respond to CRF application with a robust increase 
in firing frequency. Using a specific CRFR1 antagonist, I confirm this receptor 
mediates the increase in firing rate of GFP labeled CRFR1 expressing neurons. 
Second, using the BAC transgenic mouse line CRFR1-GFP, I provide evidence that 
CRFR1 expressing GPe neurons are of the prototypic subtype. I provide evidence that 
CRF-positive neurons send projections that terminate in close proximity to CRFR1 
expressing neurons in the GPe. To validate that synapses are formed between CRF 
neurons and CRFR1+ neurons, I performed rabies viral mediated retrograde tracing 
using the novel BAC transgenic CRFR1-cre mouse line. I provide evidence that the 
source of this CRF input to the GPe is three major stress regions: BST, CeA, and 
PVN. As I observed a small population of Npas1 neurons express CRFR1, I performed 
the identical experiment in the BAC transgenic mouse line Npas1-cre. I found that 
Npas1+ neurons receive projections from the same stress regions as CRFR1+ 
neurons. As CRFR1+ prototypic neurons and Npas1 neurons project to different brain 
regions, I hypothesized that the CRF projections onto different neuronal subtypes 
serve different functions and may have different outcomes on behavior. Consistent 
with this hypothesis, I provide evidence that CRFR1+ and Npas1+ neurons receive 
differential input from the major stress nuclei. More connections from the PVN are 
made onto CRFR1+ prototypic neurons while more connections from the CeA are 
made onto Npas1+ neurons. A limitation to this experiment is that I cannot say that all 
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of the projecting neurons are CRF neurons. This limitation is due to the fact that CRF 
neuron staining is complicated by the fact that CRF is a peptide located throughout 
the axon which makes cellular staining difficult. I tried to mitigate this limitation by ICV 
colchicine injection to stop vesicular transport allowing CRF to accumulate in the cell 
body, but as a result, I am only able able to visualize some CRF neurons.  
I observed that the GPe contains a microcircuit where CRFR1 prototypic 
neurons receive projections only from prototypic neurons and do not receive 
projections from arkypallidal neurons. The microcircuit formed by Npas1 neurons is 
less clear, but I speculate that they may form a bridge between prototypic and 
arkypallidal neurons or possibly that arkypallidal neurons only send projections and 
synapse on other arkypallidal neurons, in addition to their STR target. This would 
create a minimum of two circuits in the GPe in support of my hypothesis that the two 
neuronal subtypes serve different functions. Finally, I performed behavioral testing of 
both Cre lines in anxiety-related paradigms. I activated CRFR1+ neurons and found 
that anxiety-related behavior and movement in protected regions of the arena are 
increased. I activated Npas1+ neurons and found the opposite behavior. Npas1+ 
neuron activation led to reduced anxiety-related behavior and movement. Combining 
the conclusions from all three behavioral paradigms (LDT, marble burying, and OFA), 
I uncovered that the GPe likely contributes to the stress response and mediates 
anxiety-related behavior through different neuronal subtypes. This study has provided 
novel findings to both the BG and stress research fields and will serve as the basis for 
future study into the GPe-mediated stress response and anxiety-related behavior. In 
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the next sections, we will explore some of these ideas and possibilities that may arise 
when these circuits are dysfunctional.  
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Novel Circuits          
 I have provided novel evidence that three of the major stress nuclei (BSTld, 
PVN, and CeA) are sources of CRF neuronal input to the GPe. Moreover, different 
GPe neuronal subtypes receive differential synaptic input from these major stress 
nuclei (Fig.25 A). Npas1 expressing neurons receive a greater proportion of CRF input 
from the CeA while CRFR1 expressing neurons receive a greater proportion of CRF 
input from the PVN. The question is raised of how the stress response is affected by 
this novel circuitry. It is plausible that at the initiation of the stress response PVN 
neurons releasing CRF into the hypophyseal portal may also release CRF into the 
GPe. This release may happen either through volume diffusion or synaptically, or 
possible by both mechanisms. Activation of these neurons by CRF may serve to 
increase both anxiety-related behavior and movement effectively alerting an organism 
to a potential threat and biasing BG output to allow the anxiety component of 
movement to dominate motor programs. To restore homeostasis, CRF released from 
CeA neurons may act on the small population of CRFR1+ Npas1 neurons to initiate 
an anxiolytic cascade propagated by arkypallidal GPe neurons. Alternatively, CRF 
activation of Npas 1 neurons may be delayed due to CRF from the PVN diffusion time 
through the GPe. The initial wave of CRF release would activate the anxiogenic circuit 
of the GPe because CRFR1 is more abundantly expressed in prototypic neurons than 
Npas1 neurons. However, with time anxiolytic Npas1 neurons would eventually 
activate effectively reducing the anxiety initiated from the first burst of CRF from the 
PVN as it has time to diffuse and excite the small population of Npas1 neurons. 
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 I also provide evidence that a complex microcircuit exists within the GPe 
(Fig.25 B). My data illustrates that CRFR1 expressing neurons only receive input from 
prototypic neurons and not from arkypallidal neurons. In contrast, Npas1 neurons 
receive input from both prototypic and arkypallidal neurons raising the intriguing 
hypothesis that Npas1 neurons may serve as a link between prototypic and 
arkypallidal neurons. 
 As the GPe is GABAergic, it is anticipated that all internuclear communication 
between neurons would be inhibitory. However, our current models of the BG do not 
take into account different neuronal subtypes. In fact, I observed an increase in 
movement as measured by the OFA following activation of CRFR1 prototypic neurons 
and a decrease in movement following activation of Npas1 neurons. In the classic 
model of the BG, increased activation of the pallidosubthalamic-projecting neurons as 
caused by a decrease in D2 inhibition on the GPe should decrease movement, but I 
hypothesize that the observed increase in movement is purely a manifestation of 
anxiety. This movement process may be mediated by a limbic component of the GPe 
that may intersect with motor circuits of the BG. 
 My findings require that we rethink the classical BG model of D1 direct and D2 
indirect pathways. For many years, researches used this model to explain the 
movement phenotypes manifested in patients with neurodegenerative disorders like 
PD. However, with advances in technology, we now can dissect the neural circuitry of 
the BG to better understand how it mediates movement and other components of 
behavior. My neural tracing and behavioral data suggest that the BG has greater 
complexity than the two pathway model. While the D1/D2 pathway model has been 
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useful, it has become antiquated. Our job as researchers is to modify and add to 
existing concepts and models using new techniques and tools. My data supports a 
new model of the BG in which GPe neuronal subtypes may display differential 
responses to the CRF stress peptide to elicit contrasting behavioral and movement 
outcomes.  
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Figure 25. Novel Circuits. (A) The PVN sends more projections to CRFR1 
expressing neurons in the GPe than the CeA while the CeA sends more projections 
to Npas1 expressing neurons possibly allowing disparate functions during the stress 
response. (B) CRFR1 expressing neurons and prototypic neurons receive projections 
and send projections only to other prototypic neurons. FoxP2 arkypallidal neurons 
project to other FoxP2 arkypallidal neurons. Npas1 neurons act as a bridge allowing 
prototypic information to reach FoxP2 arkypallidal neurons. GPe = external globus 
pallidus; CeA = central amygdala; PVN = paraventricular nucleus of the 
hypothalamus; 3V = 3rd ventricle. 
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Dysregulation of CRF and the HPA-axis Leads to Neuropsychiatric Disease 
	
Psychiatric illnesses such as anxiety disorders and depression are among the 
most common mental disorders and present a serious public health epidemic 
(Bonfiglio et al., 2011; Risbrough and Stein, 2006). Those who suffer from anxiety 
disorders often are severely disabled by the disease and experience a profound 
reduction in quality of life. Stress is an etiologic factor in psychiatric illnesses, 
especially in anxiety disorders. Therefore, the study of stress, anxiety-related 
behavior, and the stress response is crucial to further our understanding of the 
mechanisms underlying psychiatric illnesses (Aubry, 2013; Binder and Nemeroff, 
2009). Many anxiety-related disorders are believed to originate from dysfunction of 
neural circuits that respond to stress (Ressler and Mayberg, 2007). The circuits drive 
stress hormone secretion via the HPA-axis (Anthony et al., 2014; Risbrough and Stein, 
2006; Tovote et al., 2015). They also project directly to important stress-activated 
nuclei such as the amygdala and BST to directly modulate behavior (Flandreau et al., 
2012; Stokes and Sikes, 1991). As discussed, the stress-responsive circuitry is unified 
by the expression and localization of CRF and its receptors CRFR1 and CRFR2.  
Dysregulated CRF circuits are involved in neuroendocrinological disturbances 
and over 20 years of preclinical studies have pointed to CRF as a major factor in 
psychiatric illnesses including anxiety and depression (Binder and Nemeroff, 2009; 
Risbrough and Stein, 2006). CRF expression has been shown to be elevated in 
depressed individuals. Also, elevated levels of CRF have been detected in the 
cerebrospinal fluid (CSF) of depressed individuals, which is due to overactive extra-
hypothalamic CRF neurons (Arborelius, 1999). These finding have spurred the 
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investigation of antagonism of the receptor responsible for the anxiogenic effects of 
CRF, CRFR1 (Hauger et al., 2009). CRFR1 antagonism has not been successful in 
clinical trials pointing to the fact that we still do not understand the complexity of CRF 
action and how CRF acts to drive anxiety, anxiety-related disease, and other 
psychiatric illnesses (Howerton et al., 2014). 
When CRF is hypersecreted, the originally beneficial effects of HPA-axis 
activation turn into increased risk for the development of depression- and anxiety-like 
behavior (Landgraf, 2006). In transgenic mice that overexpress CRF, there are 
noticeable depression- and anxiety-related symptoms (Britton et al., 1986; Pepin et 
al., 1992; Ströhle et al., 1998).  In addition, CRF overexpression has been linked to 
anxiety and hyperlocomotion (Coste et al., 2001; Stenzel-Poore et al., 1996). 
Interestingly, I observed the same behavior following DREADD activation of CRFR1 
neurons in the GPe. It is possible that DREADD mediated chronic activation of CRFR1 
in the GPe mimics the effects of CRF oversecretion.   
Excessive CRF secretion leads to HPA-axis overactivity (increased release of 
ACTH and Cort) which occurs in 50-80% of individuals diagnosed with depression and 
therefore the functioning of the HPA-axis has received attention as a potential 
biomarker for depression (Heuser et al., 1994). Moreover, activation of the HPA-axis 
activity may be a useful indicator of treatment response because HPA-axis 
hyperactivity is correlated to an increased risk for a reoccurrence of depression (Zobel 
et al., 2001). Hypersecretion of CRF leads to increased Cort, therefore glucocorticoids 
have been linked to depression. Although higher Cort is most often seen in patients 
with depression, CRF dysregulation can lead to greater or diminished Cort secretion 
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(Abelson et al., 2006; Cookson et al., 1985; Vincent and Jacobson, 2014). HPA-axis 
dysregulation that leads to increased ACTH secretion has also been observed in 
individuals with panic disorder, an extreme form of anxiety disorder in which patients 
experience disabling panic attacks sometimes without environmental cues or an 
apparent stressor (Abelson et al., 2006).  
As the prefrontal cortex (PFC) plays a primary role in translating stressful 
emotional information into action, dysregulation of GRs in the PFC has been 
implicated in major depressive disorder (MDD) and posttraumatic stress disorder 
(PTSD) (McKlveen et al., 2013). Additionally, the PFC, which interprets emotional 
stress levels, expresses abundant GRs which are proposed to be regulators of 
feedback control of the HPA-axis (Diorio et al., 1993; Fuxe et al., 1985; Meaney et al., 
1985; Radley et al., 2006; Reul and de Kloet, 1986). This indicates that overactivity of 
GRs in the PFC may play a role in pathological negative feedback to the HPA-axis. In 
addition, chronic activation of PFC GRs by chronic stress disrupts GR expression 
resulting in dendritic atrophy, spine loss, and altered neuronal excitability, which 
causes a loss of PFC HPA-axis regulation (Goldwater et al., 2009; Mizoguchi et al., 
2003; Radley et al., 2008, 2004). This suggests that elevated levels of Cort secretion 
in the PFC may play a role in stress-related diseases such as depression and anxiety 
(Pariante and Miller, 2001; Price and Drevets, 2012). 
To test the negative feedback of the HPA-axis, the dexamethasone 
suppression test (DST) uses the synthetic glucocorticoid dexamethasone. In 
depressed patients, the activity of the drug does not suppress levels of ACTH and 
Cort providing a possible mechanism by which the HPA-axis is hyperactive. In 
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contrast, DST suppresses levels of ACTH and Cort in control individuals indicating an 
intact negative feedback in the HPA-axis. In a mouse model of high anxiety-related 
behavior and depressive behavior, it was found that the mice experienced a lower 
level of HPA-axis reactivity (Arborelius, 1999; Sotnikov et al., 2014).  In sum, any 
dysregulation in the HPA-axis can lead to behaviors experienced by individuals with 
psychiatric diseases (Arborelius, 1999).  
A more sensitive neuroendocrine test to reveal HPA-axis dysregulation 
combines the DST with the CRF stimulation test. Patients undergoing this test are first 
administered a single dose of dexamethasone at midnight and the following day 
receive an intravenous injection of a low dose of CRF. The amount of ACTH and Cort 
released is much higher among individuals that suffer with depression (Holsboer et 
al., 1995). The DST and dex/CRF test have different results most likely because the 
dose of CRF can enter the CNS and activate CRFR1, while dexamethasone cannot 
enter the CNS and thus cannot activate CRFR1. In fact, the study proposes that it can 
detect depression with an accuracy of 80% (Heuser et al., 1994). 
The HPA-axis is very sensitive to early stress exposure. Experiments that 
stressed pregnant female mice showed that the pups had increased HPA-axis activity 
throughout adulthood. On the other hand, very brief daily separation of mother and 
pups results in a reduction of both emotionality and Cort secretion in adulthood (Levine 
and Mullins, 1966; Reul et al., 1994). It becomes apparent that either a hypo- or hyper-
active HPA-axis can manifest as psychiatric illness. While most psychiatric illnesses 
have been associated with a hyperactive HPA-axis, PTSD has been linked to a 
hypoactive HPA-axis (Justice et al., 2015).   
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Additionally, early life stress has been shown to play a role in the adult stress 
responses. In humans, sustained stress exposure in adolescence from extreme 
deprivation and abuse has been linked to sensitization of CRFR1 mediated stress 
responses and exaggerated responses to stressors (Heim et al., 2008). Acute and 
chronic stress during early life increases the amount of CRF located in the locus 
coeruleus (LC) noradrenergic system, a member of the CAS system that is vital to the 
stress response. The activity of LC noradrenergic systems is elevated during times of 
stress and anxiety in humans. This evidence suggests that overactivation of the CRF 
network and the HPA-axis, whether during early life or adulthood, are a major driver 
of psychiatric illnesses such as anxiety and depression.  
It has been proposed, although not proven, that antidepressant efficacy is due 
to normalization of the HPA-axis. This hypothesis was generated after it was observed 
that in depressed patients cortisol secretion is elevated. Additionally, the number of 
CRF neurons and CRF concentrations in limbic brain regions is increased; however, 
the number of CRF binding sites in the cortex is reduced (Holsboer, 2000).  
It is important to discuss the behavioral paradigms used to measure 
depressive-like behavior in mice for future researchers. Previously, I discussed 
behavioral paradigms that test anxiety-related behavior in mice. Depressive-like 
behavior in mice is measured mainly by two behavioral paradigms; the forced swim 
test (FST) and the tail suspension test (TST). In the forced swim test, a mouse is 
placed in a beaker of water and the length of time it swims before giving up and floats 
is interpreted as a level of depression. The longer the mouse swims, it is interpreted 
as less depressive-like behavior (Choi et al., 2013; Vincent and Jacobson, 2014). In 
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the tail suspension test, a mouse is attached to a hook by the tail and the time it 
struggles to become free is measured. The time immobile is interpreted as depressive-
like behavior where a longer time immobile equates to higher depressive-like behavior 
(Solich et al., 2015; Vucković et al., 2008).   
In summarizing this discussion, it can be concluded that CRF and HPA-axis 
activity, along with specific brain structures, play a major role in the development of 
pathological stress-related diseases such as anxiety and depression.	
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CRF’s Potential Role in the Symptoms of Parkinson’s Disease 
	
 Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder following Alzheimer's Disease. It has an incident rate of 2% of the adult 
population over 60 (Dhungel et al., 2015; Massano and Bhatia, 2012). Only 10% of 
PD cases are linked to genetic causes while the remaining 90% are considered 
sporadic with unknown origin (Kibel and Drenjančević-Perić, 2008). The disease is 
generally thought of as a motor disease caused by the death of dopaminergic neurons 
in the substantia nigra pars compacta (SNc) resulting in a loss of dopaminergic 
neurotransmission in the STR (Obeso et al., 2014). The motor aspects of the disease 
are categorized by four distinct features: bradykinesia (slow movement), rest tremor, 
rigidity, and postural and gait impairments (Massano and Bhatia, 2012). 
Neuropsychiatric disorders of anxiety and depression are key non-motor symptoms of 
the disease that aid in diagnosis and are found in 40-50% of PD patients (Massano 
and Bhatia, 2012; Yamanishi et al., 2013). Surprisingly, the non-motor symptoms of 
the disease are only recently garnering attention as part of the primary features of PD. 
Mood swings linked to varying degrees of motor functioning are reported in 66% of 
PD patients. These aspects can be correlated by the occurrence of decreased mood 
and high anxiety with poor motor function (Vlastelica, 2011). 
 Stress can exaggerate the motor deficits in PD. Specifically, chronic stress and 
the associated neuroendocrine response can produce a neurotoxic effect that can 
lead to the death of dopaminergic neurons in the SNc (de Pablos et al., 2014; Smith 
et al., 2002, 2008). Since stress has the potential to cause the loss of dopaminergic 
neurons and is implicated in the etiology of neuropsychiatric disorders like anxiety and 
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depression, the potential for a link between the motor and non-motor symptoms of PD 
emerges through the stress pathways (Krishnan and Nestler, 2008; Nestler et al., 
2002). Investigating the circuitry controlling the body’s response to stress could 
provide crucial insights into the pathogenesis of PD and lead to new targets for 
therapeutics. From the evidence presented in this study, I propose this link to be the 
GPe.  
 GPe function is greatly disrupted in the dopamine depleted brain. In a 6-OHDA 
mouse model of PD, dopamine depletion was shown to decrease autonomous activity 
in Npas1 neurons, while PV+/prototypic neuron firing is preserved (Hernandez et al., 
2015). In my behavioral study, I have shown that CRFR1 expressing prototypic 
neuronal activation leads to an increase in anxiety-related behavior and an increase 
in movement in protected regions of the maze. I have shown that activation of Npas1 
neurons, which are mostly arkypallidal (all arkypallidal neurons are Npas1+), leads to 
a reduction in anxiety-related behavior and decreased movement in the protected 
regions of the maze. Interpreting my results in the context of a PD model, a decrease 
in the activity of Npas1 neurons could drive anxiety by allowing CRF activation of 
CRFR1 expressing GPe neurons to proceed without the counterbalancing effect of 
Npas1 neuronal connections to the STR. This suggest that anxiety-related behavior 
mediated by the GPe can be “selected” based on which neuronal subtype is firing and 
that there is a mechanism of balance between the two neuronal subtypes, similar to 
the direct and indirect pathway model. Activation of CRFR1 neurons increases 
movement via the direct pathway while activation of Npas1 neurons decreases 
movement via the indirect pathway. This revised model improves upon the once-held 
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belief that the GPe is a homogenous nucleus with a single function in the indirect 
pathway (Albin et al., 1989; Alexander and Crutcher, 1990; Calabresi et al., 2014; Y. 
Smith et al., 1998; Wichmann and DeLong, 1996). Based on my findings, I predict that 
GPe neurons in dopamine depleted brains would display increased excitability due to 
altered striatal GABAergic input, which would manifest as increased anxiety-related 
behavior. Arkypallidal neurons may decrease their inhibitory input to the STR leading 
to a decrease in movement similar to what is observed in PD. We are just beginning 
to understand the Arkypallidal-STR pathway so this may not be the case in PD. As the 
GPe is highly dysfunctional in PD, any aberrant signaling may lead to both motor and 
non-motor symptoms as I have shown the GPe is involved in both motor and anxiety-
related behavior.  
 In response to a physiological stressor such as neurodegeneration of 
dopaminergic neurons in the SNc, the stress response is activated. PVN release of 
CRF into the GPe resulting in increased movement via activation of the direct pathway 
counterbalanced by decreased movement controlled by Npas1 neurons in the indirect 
pathway may lead to such symptoms as tremors (shaking of the hands). As the 
severity of motor symptoms are correlated to the severity of the non-motor symptoms 
including depression and anxiety, it is not unreasonable to consider that increased 
CRF signaling as a result of activation of the stress response accounts for this 
correlation. 
 As discussed, the GPe is in a powerful position to exert its influence on all 
“downstream” nuclei of the basal ganglia. A dysfunctional GPe receiving excitatory 
CRF input likely precipitates anxiety-related disorders. Also, it is possibile that a 
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dysfunctional GPe could manifest as elevated arkypallidal activity and a “no stress” 
response to normal stressors. As I have shown that the GPe has bidirectional control 
over anxiety-related behavior, we can consider the GPe as an anxiety BG nucleus. 
Any reduced firing in anxiolytic Npas1 GPe neurons, like the ones experienced in 
models of PD, is likely to manifest as an increase in anxiety-related behavior, possibly 
reaching the levels of panic disorder which half of PD patients experience. The 
question is whether CRF signaling plays a role in this anxiety or does the dysfunction 
in the GPe alone contribute to the psychiatric symptoms experienced by PD patients. 
Excessive CRF signaling to the GPe, as part of the stress response activated by the 
loss of dopaminergic neurons, could manifest not only as anxiety-related behaviors 
and illnesses. Most PD patients also experience depression. As discussed in the 
previous section, hypersecretion of CRF is a hallmark of depression. In this way, 
elevated CRF signaling and GPe dysfunction could lead to both motor and non-motor 
neuropsychiatric disorders that plague PD patients. 
 The question arises as to whether an individual with a predisposition to anxiety 
disorders, either through natural processes like early life stressors or genetic causes 
such as polymorphisms in CRF receptors, is predisposed to develop PD. Based on 
known PD progression, it seems likely that an early symptom of PD would be anxiety 
that gradually increases as dopamine levels decrease. The loss of dopamine would 
amplify GPe dysfunction as any changes in signaling in the STR will be propagated to 
the GPe. By identifying the GPe as an anxiety nucleus in the BG that receives input 
from the stress system in the form of CRF/CRFR1 signaling, the GPe could serve as 
a link between the psychiatric and motor symptoms of PD. 
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 This body of work may set the stage for new interventions that could address 
both motor and psychiatric aspects of PD. With further advances in technology, a 
synthetic peptide CRFR1 antagonist that crosses the blood brain barrier will be 
generated. I predict that this antagonist would improve the functioning of PD patients 
by attenuating the deterioration of motor and non-motor behaviors. Considering my 
hypothesis that PD symptoms are the result of imbalanced prototypic and arkypallidal 
neuronal activity in the GPe, activating arkypallidal neurons may be a beneficial 
treatment for anxiety.  
It would be interesting to repeat the same DREADD experiments in 6-OHDA 
PD mouse models to determine how GPe mediated anxiety-related behavior and 
movement are effected in the absence of striatal dopamine. If an excitatory receptor 
expressed abundantly in Npas1 neurons is identified, a novel agonist could be 
generated to activate these neurons to lessen anxiety. In combination with the next 
generation of CRF antagonist, an Npas1 excitatory agonist acting primarily in the GPe 
may restore the delicate balance that is disrupted by dopamine depletion. As 
discussed in the introduction, dopamine depletion directly effects the STR by 
generating an imbalance in D1 excitatory receptor and D2 inhibitory receptor 
activation. The STR then propagates this dysfunction “downstream” to the GPe. If we 
could develop drugs that act on the GPe and/or inputs to the GPe from the STR, we 
may not be able to stop the progression of PD, but we could improve the quality of life 
of PD patients dramatically.  
Additionally, identifying the GPe as a likely CRF responsive nucleus that has 
bidirectional control over anxiety-related behavior could lead to the GPe being a target 
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for therapeutics such as deep brain stimulation (DBS). Due to the heterogeneity of 
brain regions where DBS electrodes are placed and the relevant target neuronal 
subtypes e.g. prototypic vs arkypallidal neurons, it has been difficult to reveal the 
underlying mechanisms of DBS, however high-frequency stimulation of the STN is 
beneficial in the treatment of PD (Gradinaru et al., 2009). It is possible that DBS in the 
GPe may be effective in treating anxiety, and in addition, the motor symptoms of PD. 
Experiments in humans need to be performed before we can draw this conclusion 	
While these proposals will require years of intensive research and decades of 
drug development, I believe that I have laid the groundwork for future research into 
the role of the GPe in anxiety and the possibility of generating targeted therapeutics 
to improve the lives of those suffering from PD.  
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Anxiety-related Behavior and Movement as GPe Mediated Action Selection 
	
As discussed in the introduction, a recent computer model of the GPe 
calculates that prototypic and arkypallidal neurons are capable of optimal action 
selection (Bogacz et al., 2016). Action selection can be reflective (goal-directed 
behavior) or reflexive (habitual behavior) (Dolan and Dayan, 2013). Goal-directed 
behavior can be defined as involving active deliberation and adaptive flexibility to a 
changing environment. On the other hand, habitual behavior can be defined by its 
automaticity and inflexibility (Dayan, 2009; Dolan and Dayan, 2013).  
I observe an increase in anxiety-related behavior and movement when 
activating CRFR1+/prototypic neurons, and a reduction in the same behaviors when 
activating Npas1+/arkypallidal neurons. Of the behavioral paradigms, I will consider 
the OFA in the process of the proposed role of the GPe in action selection. When 
prototypic neurons (CRFR1-cre) neurons are activated, I observe an increase in 
anxiety-related behavior as measured by a decrease in the ratio of time spent in the 
center region versus total time. Also, I observe an increase in the total distance 
traveled in the surround of the maze, a region that elicits the least anxiety. Since the 
increase in movement was region specific; I concluded that it was a component of the 
anxiety-related behavior. While the conventional interpretation of the OFA results 
clearly demonstrates an increase in anxiety-related behavior, movement in the 
surround is not a measure of anxiety by convention (Green et al., 2007).  
In the classic model of the BG, activating prototypic neurons that project to the 
STN should result in decreased movement, not increased movement as I observe 
(Hernández et al., 2015). This suggests that activation of prototypic neurons, in 
	 136	
isolation, have a function not described by the direct/indirect pathway model. Possibly, 
this discrepancy can be explained by the GPe’s proposed role in action selection.  
Activation of the stress response by CRF/CRFR1 signaling necessitates action 
selection in the behaving animal. My data demonstrates that anxiety-related behavior 
is mediated by prototypic neuron activation in the GPe. In response to a stressor, all 
actions that are salient to survival should take precedence in BG motor programs. 
Now that an action must be selected for survival, escape is the reflective/goal-directed 
behavioral action that may be chosen (Hauger et al., 2009). The opposite action that 
may be selected is the reflexive/habitual action for the animal to freeze (Botta et al., 
2015; Dickinson, 1985; Dickinson and Balleine, 1994; Snyder et al., 1985; Stricker 
and Zigmond, 1974). This is the classical “flight or fight” dilemma in the initiation of the 
stress response. Specifically, when faced by a stressor, the animal has two choices. 
This is action selection where the most salient for survival should be chosen. If there 
are two choices for the animal to make, escape or freeze, why did all of my mice select 
to escape? 
DREADD activation of prototypic neurons is by definition an artificial 
manipulation in an artificial system, Cre expressing mice. As the mice were naive to 
the OFA when tested, the action they selected, escape, was goal-directed behavior 
and not habitual. Further, escape behavior is a goal-directed behavior because it is 
intentional and has a beneficial outcome (Dolan and Dayan, 2013). However, I have 
generated a total BG network disturbance by my artificial manipulation in the GPe. 
This manipulation must have an effect on all of the “downstream” nuclei in the BG and 
on the feedback the GPe and output nuclei of the BG receive. As the mice have 
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experienced anxiety previously, some of the mice should have made the reflexive or 
habitual action selection and displayed freezing behavior. I propose that artificial 
activation of prototypic neurons in the GPe impairs the ability of the GPe to make the 
optimal action selection and the system biases to one choice, escape. My 
manipulation has disrupted the ability for the GPe to make a choice between reflective 
or reflexive behaviors in response to the anxiety-eliciting stimulus. Potentially, the 
network of the BG is biased to the selection of the goal-directed action, and this leads 
to the increased movement in contradiction to the GPe playing its classical role in the 
BG indirect pathway. 
On the other hand, when I artificially activate arkypallidal neurons as in 
DREADD activation of Npas1 neurons, I observe less anxiety-related behavior and 
movement. In the OFA paradigm, the mice do not select either to escape or to freeze. 
The mice display more center region time and more exploratory behavior, which is 
indicative of a decrease in anxiety-related behavior. I propose that activation of 
arkypallidal neurons in the GPe impairs the ability of the BG to select the appropriate 
action (similar to activation of prototypic neurons). Arkypallidal neurons project to and 
send a “stop” signal to the STR. Activation of these neurons would modify the normal 
functioning of the STR which has been shown to play a role in both goal-directed and 
habitual behaviors (Balleine, 2005; Corbit and Balleine, 2005; Killcross and 
Coutureau, 2003; White, 1997; Yin et al., 2005, 2004; Yin and Knowlton, 2006). It is 
not unreasonable to propose that artificial disruption in the STR may render the GPe’s 
proposed role in optimal action selection dysfunctional, resulting in no action being 
selected. The mice just explore the maze which my data supports. 
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 While my behavioral paradigms indicate an increase in anxiety-related 
behavior in the case of activation of prototypic neurons, the movement phenotype I 
observe in the OFA may be an artifact of an artificial system. However, the phenotype 
may provide novel evidence that the unmanipulated GPe is capable of optimal action 
selection because disruption in GPe circuits has a deleterious effect on action 
selection (Bogacz et al., 2016). In vivo electrophysiological recordings of prototypic 
and arkypallidal neurons in the GPe during DREADD manipulation in paradigms 
designed to test action selection (reinforcer devaluation paradigms) may provide 
evidence to support this proposal. 
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Concluding Remarks 
	
 This study provided the first evidence that a BG nucleus, the GPe, has 
bidirectional control over anxiety-related behavior and movement that can be 
influenced by CRF/CRFR1 signaling. The two neuronal subtypes I investigated, 
CRFR1-expressing prototypic neurons and Npas1 neurons, have opposing behavioral 
outcomes in anxiety-related behavioral paradigms. It would be of interest to test these 
mice on behavioral paradigms that focus on other aspects of behavior such as 
learning and memory as action selection moving from goal-directed behavior to 
habitual behavior is a form of learning (Dolan and Dayan, 2013). Also, it would be of 
great interest to inhibit one neuronal subtype while activating the other to further 
investigate the GPe’s role in action selection. With the ever growing field of mouse 
genetics, the technology to do this already exists. 
 I identified, for the first time, the source of CRF input to the GPe and discovered 
that CRF neurons in the key stress-nuclei project and synapse in the GPe on both 
CRFR1 neurons and Npas1 neurons.  
In conclusion, this study has provided a foundation that identified the GPe as a 
BG nucleus that’s neuronal subtypes have bidirectional control over anxiety-related 
behavior and movement. Future researchers who wish to investigate CRF/CRFR1 
signaling in the GPe, or to investigate basal ganglia-mediated anxiety-related 
behaviors, will hopefully find this body of work beneficial to both the BG and stress 
fields. 
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